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Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2007 
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    Serotonin was first discovered in the late 1940s as a vasotonic factor and is now  
considered a principal neurotransmitter in the nervous system. 5-HT6 receptors are one of 
the most recently identified members of the serotonin receptor family which consists of 
seven classes (5-HT1-5-HT7). 5-HT6 receptors are G-protein coupled, positively     
coupled to an adenylate cyclase second messenger system and are primarily found in the 
central nervous system (CNS). The exact functional role of 5-HT6 receptors has not been 
determined, but is implicated to have possible involvement in certain neuropsychiatric 
disorders and cognition. To investigate the functional role of these receptors, it is useful 
to identify 5-HT6 selective ligands as pharmacological tools. 
 
 Our laboratory identified one of the first 5-HT6 receptor antagonists: the 
arylsulfonamide MS-245 (14a). It has been assumed that a sulfonyl (i.e., SO2) moiety is 
important for the binding of arylsulfonamides at 5-HT6 receptors. We now have 
identified benzyl analog 33 (R=H) as a single example of a non-sulfonyl analog that 
retains affinity. This questions the importance of the SO2 group and whether an aryl 
moiety or other hydrophobic groups (of equal or greater hydrophibicity) is required for 
binding. The purpose of the present investigation was to determine if the SO2, and the 
aryl moieties are required for high affinity binding. N1-Alkylsulfonyl- 78, and N1-benzyl-
substituted tryptamines 33 were synthesized and affinities compared with their 
corresponding N1-benzenesulfonyl-substituted counterparts 31 at h5-HT6 receptors. 
None of the alkylsulfonyl or benzyl analogs displayed and/or retained the affinity of 
the simple benzenesulfonyl tryptamine analog (31a) (Ki = 4.1 nM). The results show that 
an arylsulfonyl group at the tryptamine N1 position is optimal, relative to an alkylsulfonyl 
group, for 5-HT6 receptor affinity. In a comparative analysis utilizing six pairs of 
tryptamines, it was found that there was little correspondence (r2 = 0.048) between the 5-
HT6 receptor affinities of the examined benzyl and benzenesulfonyl pairs. Current 
findings indicate that an aryl (or substituted aryl)sulfonyl (rather than  benzyl) moiety is 
optimal for high affinity binding, and further suggest that N1-benzenesulfonyl- and their 
corresponding N1-benzyltryptamine counterparts bind in a different fashion. 
 
 
                      
                                               
                                                                                                                                            
1 
 
                                                              I. Introduction 
 
       Increasing evidence and awareness indicate that treatment of neuropsychiatric 
disorders such as depression, psychosis (e.g., schizophrenia) and cognition is a viable and 
productive endeavor. Tricyclic antidepressants (TCAs), modern selective reuptake 
inhibitors, and antipsychotics remain the mainstay in pharmacologic treatment of these 
disorders.1 However, the development of neuropsychiatric disorder medications that are 
effective but free of serious side effects remains a major focus in the field of drug 
discovery. Therefore, development of safe and effective medications represents a 
considerable therapeutic opportunity. This process of new drug development has 
continued to change greatly in the last five decades and is likely to change even more 
rapidly in the immediate future.2
       The history of the first major class of neuropsychiatric disorder medications, 
antipsychotics, began in 1883, when phenothiazine was first synthesized by Bernthesen. 
However, phenothiazines were not introduced  into human pharmacology until the late 
1940’s when they were first investigated as possible antihelmintic agents and later as 
antihistamines.3 Later,  Charpentier (of Rhone-Poulenc Pharmaceuticals) synthesized a 
new derivative of phenothiazine, chlorpromazine, and in early 1952, French psychiatrists,  
Delay and Deniker, first reported chlorpromazine’s antipsychotic activity, particularly for 
the treatment of schizophrenia – a serendipitous discovery.4
       The discoveries of the antidepressant properties both of tricyclic agents and 
monoamine oxidase (MAO) inhibitors, first generation antidepressants, were the 
2 
fortuitous and unexpected consequences of tangential avenues of research. While 
investigating the antipsychotic activity of imipramine (which is structurally similar to the 
phenothiazines), the Swiss clinical researcher Kuhn (1958) found that although it was 
ineffective in schizophrenia it produced considerable improvements in depressed patients. 
Similar serendipitous findings contributed to the development of MAO inhibitors when 
iproniazid, the first of these agents, was found to produce mood elevation and euphoria 
(as side effects) in tuberculosis patients. It is important to note that this discovery was 
subsequent to the discovery by Thiele and Holzinger in 1889 of iminodibenzyl.5  The 
new generation of antidepressants involves the use of selective serotonin reuptake 
inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), mixed action 
agents, and alternative (nontraditional) antidepressants.6
       The discovery of dopaminergic receptor-blocking capabilities, especially in the 
mesolimbic dopamine pathway, of conventional antipsychotic drugs led to the dopamine 
hypothesis of schizophrenia.7 Conventional antipsychotics were found to be effective in 
controlling psychotic symptoms, such as hallucinations, delusions and agitation, and in 
reducing both morbidity and mortality.7 However, they have significant side effects such 
as extrapyramidal effects (EPS), weight gain, cardiovascular liabilities and type II 
diabetes.8,9 In the 1960s and 1970s, clozapine, the first of the second generation of 
antipsychotics, was introduced into clinical practice. It was called an atypical 
antipsychotic because it produced few, if any, EPS at clinically effective doses in 
humans. Other examples are known, such as fluperlapine, melperone and thiosperone.9 
Since 1990, this second generation of antipsychotic drugs has led to dramatic shifts in the 
treatment of major mental illness. It has been postulated that this unique property is due 
3 
their affinity for receptors of the serotonergic neurotransmitter system in addition to their 
effects on dopamine D2 receptors.10 Most of the atypical antipsychotics, with the 
exception of the substituted benzamides such as amisulpride, have, in addition to D2 
receptor antagonism or partial agonism, high affinity for 5-hydroxytryptamine (5-HT)2A 
receptors and function as inverse agonists at this receptor.11,12 In addition, some, but not 
all, are 5-HT2C, 5-HT6 and 5-HT7 receptor antagonists, as well as direct or indirect 5-
HT1A receptor agonists.13,14  
       Schizophrenia appears to be associated with decline  in general cognitive function at 
some point during the course of the illness.10 One approach to the development of new 
agents for schizophrenia to improve functional outcomes is focusing on cognitive 
impairment (for example, attention deficits, working memory deficits, and deficits in 
executive function).15,16 Achievements in treating cognitive impairments may 
tremendously contribute to treating other components of cognition deficits (for example, 
memory and learning disorders). Conventional antipsychotics appear to produce little 
benefit in cognitive function, but atypical antipsychotics may reduce cognitive 
impairments.17 However, in general, conventional antipsychotic drugs, which act on 
dopamine D2 and 5-HT2 serotonin receptors, are limited in their ability to treat cognitive 
deficits.18 Serotonin receptors (specifically 5-HT6 receptors) have been implicated in 
cognitive processes such as memory.19,20 The 5-HT6 receptor has a unique 
pharmacological profile, including a high affinity both for typical, such as 
chlorpromazine, and atypical, such as clozapine and olanzapine, antipsychotics.21 To 
further investigate the functional role of 5-HT6 receptors, it is necessary to identify 5-HT6 
selective ligands as pharmacological tools. Much work is ongoing to develop selective 
4 
novel agents with unique pharmacological effects that may enhance cognition and other 
neuropsychiatric disorders. One of the first examples of a 5-HT6 receptor antagonists was 
the N1-arylsulfonyltryptamine MS-245 – an agent developed in our laboratories. The 
purpose of the present study was to investigate further the binding of N1-substituted 
tryptamines at h5-HT6 receptors in order to better understand their binding requirements. 
This work can lead to further investigation of the functional role of h5-HT6 receptors 
geared towards developing an effective and safe treatment for neuropsychiatric and 
cognitive disorders. 
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                                                              II. Background 
 
1. Neuropsychiatric disorders and cognition.                                                              
       Since the current drugs for neuropsychiatric disorders and cognition are of moderate 
safety and efficacy, they are far from ideal. Continued discovery and development 
efforts, aimed to relieving these shortfalls, is greatly dependent on a clear biomedical 
understanding of the underlying disease process, and the psychosocial aspects of the 
illness.22 As mentioned earlier, these disorders include depression, psychosis (e.g., 
schizophrenia), and cognition. 
 
1.1 Depression: 
       The term “depression” can refer to a clinical syndrome, such as a primary or 
secondary affective disorder, and a symptom in the sense of being severely “sad” or 
“unhappy”.23 Furthermore, the term “depression” may be used by a patient to 
communicate problems of cognition, perception, mobility and behavior as well as affect 
and mood. This is to be expected given the interdependence of the components which 
make up the composite mental state.23 Depression disorders constitute a great burden to 
society. Disability associated with depression is greater than that reported for other 
chronic physical conditions such as hypertension, diabetes, arthritis, and back pain.24,25 
Depression is a common condition that has both emotional and physical aspects.23,26  
Physical manifestations, common features of depression, are present in up to 80% of 
depressed patients.27,28 The diversity of clinical symptoms argues against an etiology 
associated with single brain location, lesion type, or neurochemical system. Rather, the 
6 
associated impairment of cognitive, motor, somatic, and circadian functions in patients 
with dysphoria suggest that depression is a composite disorder affecting discrete but 
functionally interconnected limbic, paralimbic, and neocortical circuits.29,30 Depression 
may accompany a variety of neurological, psychiatric, and other medical illnesses, and 
recognition of these cormobid conditions can influence the approach to treatment as well 
as therapeutic outcome.31  No single neurotransmitter abnormality has been identified that 
fully explains the pathophysiology of the depressive disorders or the associated 
constellation of mood, motor, cognitive, and somatic manifestations.32 Changes in 
norepinephrine, serotonin, dopamine, acetylcholine, opiate, and γ-aminobutyric acid 
(GABA) systems have all been reported.33-35 However, postulated disturbances in 
serotonergic (5-HT) and noradrenergic mechanisms have dominated the neurochemical 
literature on depression for more than 30 years based, in large part, on the consistent 
observations that most antidepressant drugs affect the synaptic concentrations of these 
two transmitters.36,37 Further evidence that depression is caused by a functional 
deficiency of serotonin in the brain has been reported.25,38-41 The early antidepressants 
include MAO inhibitors and TCAs; they have a delayed onset of action and have side 
effects such as dryness of the mouth, sweating, blurring of vision and, occasionally, 
tachycardia.42 Newer treatments are available: both psychologic and pharmacologic, that 
are safe and effective and that have a high degree of patient acceptability. Perhaps least 
well known is that depression is frequently a chronic or recurrent condition, and effective 
management must extend beyond the treatment of an individual episode.38
 
1.2. Psychosis:       
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     The term “psychosis” has a variety of meanings. Currently, in clinical practice in 
North America, psychotic means that the person has a biomedical brain disease or a 
chemical imbalance, requires medication, and cannot be treated with psychotherapy.43 
Psychosis includes less insight and reduced social and occupational function.22,43 
Schizophrenia is a subset of psychosis. It is widely regarded as the most severe mental 
illness, and schizophrenia cannot occur without psychosis.23 Disorders that may or may 
not have psychotic symptoms as an associated feature include depression as well as 
several cognitive disorders such as Alzheimer’s dementia.26 Schizophrenia is 
characterized by positive and negative symptoms: Positive symptoms of schizophrenia 
include hallucinations, delusions, thought disorder, and agitation. Negative symptoms are 
absence of normal attributes; they include reduced drive, social withdrawal, emptiness, 
and a flat emotional tone.22,23,43 Four decades of data demonstrate consistently and 
conclusively that antipsychotic medications have only a modest effect on psychotic 
symptoms.44-46 A role for serotonergic systems has been reported.47
        
1.3 Cognition: 
    Cognition refers to the ‘nature of memories at the highest level analysis, the 
psychological level’48 or ‘is that of the mind by which one becomes aware of the objects 
of thought and perception. It includes the processes of understanding and reason’.23 
Learning is clearly a fundamental aspect of cognitive development.49 Learning and 
memory are an integral part of our existence, yet the concept is only vaguely understood. 
One major discovery about the brain that contributes directly to our understanding of the 
cellular and molecular substrates of memory is the development of the “neuron doctrine” 
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by the Spanish anatomist Santiago Ramon y Cajal. This development won him the Nobel 
prize in 1906.48 Conceptual development in cognitive theorizing is a subdivisions of 
memory: short-term versus long-term memory (1890), encoding versus retrieval, 
retroactive versus proactive interference, anterograde versus retrograde amnesia, recent 
versus remote memory, declarative versus non declarative memory, and episodic versus 
semantic memory.50,51 Evidence shows that components of learning and memory can be 
disrupted in memory profiles of selected clinical populations: chronic alcoholism, 
unilateral brain damage, drug induced memory deficits (e.g., anticholinergics, 
benzodiazepines, some anticonvulsant medications), Alzheimer’s disease, Huntington’s 
disease, affective disorders, schizophrenia, normal aging, and amnesia. Various 
environmental conditions such as stress, pollutants, and diet can also result in cellular 
dysfunctioning and consequential problems in learning and memory.52-55 Recently, with 
the rise of modern methods of cognitive science and neuroscience, and their combination, 
many new and deep insights about the mechanisms of memory have emerged.48 Today, 
there is a consensus that neuronal changes associated with learning and memory occur at 
the level of the synapse.56 Some of the key structures thought to be involved in memory, 
in particular the dorsolateral prefrontal cortex and the hippocampus: cerebral cortex, 
amygdala, cerebellum, thalamus.49,51,55
       The use of selective serotonin (5-hydroxytrypatamine, 5-HT) agonists and 
antagonists has increased our understanding of the role of 5-HT receptors in the processes 
of learning and memory.57,58 In particular 5-HT6 serotonin receptors are located in brain 
structures associated with learning and memory. 
2. Serotonin and Serotonin receptors. 
2.1 Serotonin: 
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       Serotonin (5-hydroxytryptamine, 5-HT; 1), was first discovered in the late 1940s as a 
vasotonic factor and is now considered a principal neurotransmitter in the nervous 
system.59 As long ago as 1868 it was known that the blood contained a vasoconstrictive 
substance. This substance, released in serum by platelet breakdown, proved to be a 
problem to Page in his studies on malignant hypertension so he, together with Green and 
postdoctoral student Rapport, isolated and characterized this interfering substance, and 
named it for its vasoconstrictor properties – serotonin. However, during the same time as 
the studies by Page and colleagues, in Italy, Erspamer and Asero had been investigating a 
constituent of the gastric and enteric mucosa of mammals, and salivary glands of the 
octopus. They identified a compound, enteramine, and this substance was later 
demonstrated to be 5-HT. Gaddum, in 1950, made the observation that 5-HT is present in 
the brain.60,61 In addition, serotonin (5-HT) was detected in numerous plant and animal 
species. 5-HT has been implicated in a variety of central and peripheral physiologic 
actions: vasoconstriction and vasodilation, regulation of body temperature, sleep, and 
hormonal regulation. The structural similarity between 5-HT and the, then,  recently 
discovered hallucinogenic agent (+)lysergic acid diethylamide (LSD, 2; Figure 1) led to 
speculation that 5-HT might be involved in the mechanism of action of psychoactive 
substances, and that it might play a seminal role in various mental disorders.47,62
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Figure 1. The structures of 5-HT (1) and (+)lysergic acid diethylamide (LSD; 2).    
           
 
2.2 Classification: 
In mammals, seven populations of 5-HT receptors have been identified, 5-HT1 to 5-HT7, 
and are divided into 14 distinct subpopulations (see Table 1).62 There are six classes of 
G-protein coupled receptors, namely 5-HT1, 5-HT2, 5-HT4, 5-HT5, 5-HT6, and 5-HT7, but 
5-HT3 receptors belong to the ligand gated ion channel receptor family. Whereas other 
classes are further subdivided into subclasses, for the most part, the 5-HT6 and 5-HT7 
classes do not contain subclasses of receptors, and sequence diversity in these classes is 
provided mainly by alternative mRNA splicing.63
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Table 1. Classification and nomenclature for the various populations of 5-HT receptors.62
Populations                                        Second                                                Currently 
      and                                              messenger                                            accepted  
Subpopulations                                  System                                                 name 
5-HT1
    5-HT1A                                                AC(-)                                                5-HT1A
    5-HT1B                                                AC(-)                                                5-HT1B
    5-HT1Bβ
    5-HT1D
          5-HT1Dα                                       AC(-)                                                h5-HT1D
          5-HT1Dβ                                       AC(-)                                                h5-HT1B
    5-HT1E                                               AC(-)                                                 5-HT1E
          5-HT1Eα
          5-HT1Eβ                                        AC(-)                                                5-ht1F
    5-HT1F
5-HT2
    5-HT2                                                  PI                                                     5-HT2A
    5-HT2F                                                PI                                                     5-HT2B
    5-HT1C                                                PI                                                     5-HT2C
5-HT3
    5-HT3                                         Ion Channel                                              5-HT3
5-HT4                                                     AC(+)                                               5-HT4
    5-HT4
          5-HT4S
          5-HT4L
          5-HT 4(b)-4(d)
5-HT5
    5-HT5A                                               ?                                                     5-ht5A
    5-HT5B                                               ?                                                     5-ht5B
5-HT6
    5-HT6                                                 AC(+)                                            5-HT6
5-HT7
    5-HT7                                                 AC(+)                                            5-HT7
 
*AC = adenylate cyclase, (-):negatively coupled and (+):positively coupled; PI = phospholipase coupled 
 
2.3 Structure and Pharmacology: 
    All the 5-HT receptors, except 5-HT3 receptors, are members of the typical group A 
rhodopsin-like G protein-coupled receptor family (GPCR; Figure 2) in that they are 
predicted to possess seven transmembrane spanning helices, three intracellular loops, an 
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extracellular amino-terminus, and an intracellular carboxy-terminus. Functionally, the 
transmembrane regions serve to bind ligands, especially the endogenous ligand serotonin; 
the intracellular domains couple these receptors to various intracellular functions and, for 
the most part, the extracellular domains have uncertain functional roles.63 The true 
structures of these receptors remain unknown, although crystallization of the bovine 
rhodopsin receptor64 provides promise for the solution of the structures of the G-protein-
coupled receptors in the near future. In contrast to the G protein-coupled 5-HT receptors 
which modulate cellular activities via second messenger systems, 5-HT3 receptors 
directly activate a 5-HT-gated ion channel that causes the rapid depolarization of 
neurons. The deporalization mediated by 5-HT3 receptors is caused by a transient inward 
current, specifically the opening of a channel for cations.65                                                 
 
 
Figure 2. Schematic diagram of the general structure of G protein-coupled receptors.64                 
 
        The G-proteins derive their name from the fact that they bind the guanine nucleotide 
guanosine triphosphate (GTP) and guanosine diphosphate and possess intrinsic GTPase 
activity. The G proteins exist in cell membranes as heterotrimers composed of single α, β 
and γ subunits and are associated only loosely with neurotransmitter receptors. The 
receptors have a diverse array of signaling pathways (Figure 3).66 It is the interaction of 
receptor with the G-protein that allows the receptor to modulate the activity of different 
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effector systems, such as ion channels, phospholipase C and adenylyl cyclase (the 
enzyme that catalyzes the synthesis of cAMP). In the 5-HT family, the second 
messengers involved are activation or inhibition of adenylyl cyclase (AC), which controls 
intracellular cAMP concentrations, and activation of phosphoinositide phospholipase C 
(PI PLC) to form the second messengers inositol triphosphate (IP3) and diacylglycerol 
(DAG).66,67                               
       5-HT6 receptors are included in a family of serotonin receptors coupled to the 
stimulation of adenylyl cyclase. The form of heterotrimeric G protein involved is called 
Gs. Activation of these receptors results in the generation of free Gαs subunits, which bind 
to and, thereby, directly activate adenylyl cyclase. In addition, free βγ-subunit complexes 
activate certain subtypes of adenylyl cyclase.67
14 
                
 
Figure 3. 5-HTR signaling pathways and effectors (blue 5-HTR signal transduction in 
neurons, gray signaling linkages only in transfected cell lines, PL phospholipase, ERK 
extracellular signal-regulated kinase, PK protein kinase, IP3 inositol triphosphate, DAG 
diacylglycerol, MAPK mitogen-activated protein kinase, NOS nitric oxide synthase, AHP 
after-hyperpolarization, JAK Janus kinase, STAT transcription pathway, ih 
hyperpolarization-activated current, Epa activated exchange factor) 66
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3. 5-HT6 receptors. 
3.1 Structure: 
       The basic structure of the G-protein-coupled 5-HT receptors is similar to that 
proposed for nearly all of the GPCRs. The 5-HT6 receptors are integral membrane 
proteins that possess seven transmembrane (TM)–spanning domains connected by three 
intracellular loops (termed i1-i3 loops) and three extracellular loop (termed e1-e3 loops) 
and are positively coupled to an adenylyl cyclase second messenger system.68,69,70 Human 
5-HT6 receptors, a 440 amino acid polypeptide (see Figure 4), display 89% overall 
sequence homology with the rat and mouse 5-HT6 receptors and a high homology to 
other 5-HT receptors.71 
 
 
           Figure 4.  Schematic representation of a human 5-HT6 receptor polypeptide  
                            chain.71     
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3.2 Distribution: 
       Human 5-HT6 receptors are nearly exclusively localized in the central nervous 
system.71 Expression of 5-HT6 receptor mRNA has been detected in the striatum, nucleus 
accumbens, olfactory tubercle, hippocampus and cerebral cortex.72 Furthermore, 
antibody, antisense oligonucleotide, and radioligand-binding studies suggest that 5-HT6 
receptors are abundant in several brain regions, including cortical and limbic brain 
regions, the olfactory tubercle, caudate nucleus, hippocampus, nucleus accumbens, and 
striatum.73 Lower levels have been found in the amygdala, hypothalamus, substantia 
nigra, and cerebral cortex. No 5-HT6 mRNA has been detected in several human 
peripheral tissues.74
 
3.3 Signal transduction: 
    As mentioned earlier, 5-HT6 receptors are positively coupled to adenylate cyclase. 5-
HT6 receptors increase cellular levels of cAMP when transfected into JEG-3, COS-7, and 
HEK293 cells.75 In HEK293 cells, the increases in cAMP levels are mediated primarily 
through stimulation of AC Type 5 (AC5, a Gs-sensitive isoform), but not through CaM-
regulated AC isoforms, AC1 and AC8.76,77 In aggregate, the aforementioned signaling 
studies strongly support elevation of cAMP through Gs as the primary signaling linkage 
of 5-HT6 receptors.68-70 There are four potential regions of the GPCR that could interact 
with the G-protein; i1, i2, i3, and the cytosolic C-terminal tail. Among them, the most 
critical regions in determining the receptor/G-protein interactions have been suggested to 
be i2, i3, or the C-terminal tail.68-70 It has been demonstrated that the third intracellular 
loop region (i3) of the 5-HT6 receptor is critical for the interaction with Gαs.76,77 Until 
selective ligands were developed, exploration of 5-HT6 pharmacology was largely 
17 
dependent on the use of nonselective agents. Stimulation of adenylyl cyclase was 
employed to identify potential agonists, and antagonists that could be identified by their 
ability to attenuate 5-HT-induced cAMP formation. In the first such investigation of this 
kind, certain nonselective agents were characterized as 5-HT6 agonists with the following 
rank order of potency: 5-methoxytryptamine (9) > 5-HT (1) > 2-methyl 5-HT (11) > 5-
CT (13) >> α-methyltryptamine (4).78,79 However, owing to their lack of selectivity, they 
were of limited value for most other pharmacological studies 
 
3.4 Site directed-mutagenesis: 
    Many non-selective compounds, such as tricyclic antidepressant drugs and a large 
number of antipsychotic agents, tryptamine, and ergoline derivatives, interact with the 5-
HT6 receptors.21,80,92 Because no selective ligands were available, identification of 
functional 5-HT6 receptors in physiological preparations were only tentative. Site-
directed mutagenesis has been used to identify residues contributing to the ligand binding 
site of the 5-HT6 receptors. Results obtained from site-directed mutagenesis demonstrated 
that interactions with residues in two characteristic positions of transmembrane region V 
are important for ligand binding in several bioamines. In the 5-HT6 receptors, one of 
these residues is a threonine (Thr196); this residue interacts with the indole nitrogen of 
N1-unsubstituted ergolines and tryptamines. Another structural feature is Asp106 in TM 
III that demonstrates an ionic interaction with the positively charged nitrogen atoms of 5-
HT (1) and LSD (2).81,82
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3.5 Radioligands: 
    Tritiated Ro 63-0563 (3a) was introduced in 1998 as the first radioligand selective for 
5-HT6 receptors.83 In rat brain, [3H]Ro 63-0563 was displaced by a variety of ligands 
with the following rank of order of affinities: methiothepin (8) > LSD (2) > clozapine (5) 
≈ Ro 63-0563 (3a) > ergotamine (7) > 5-HT (1) > mianserin (6).83 Tritiated 5-HT, 
[3H]lysergic acid diethylamide ([3H]LSD), and [125I]-2-iodo LSD also have been used to 
radiolabel 5-HT6 receptors. Serotonin (5-HT) binds with moderately high affinity (Ki = 
10-150 nM).78 A variety of tryptamine derivatives have been tested and showed a 
significantly higher affinity when the 5-HT6 receptors were labeled with [3H]-5-HT, 
whereas ergoline compounds and several antagonists had higher affinities when [3H]-
LSD was used as radioligand.75
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Figure 5. Representative agents that bind at (although not necessarily selectively) 5-HT6 
receptors. 
 
3.6 Clinical significance: 
The exact clinical significance of 5-HT6 receptors has not yet been determined.62 Of 
interest is that a number of typical and atypical antipsychotic agents and trycyclic 
antidepressants bind at 5-HT6 receptors with Ki values in the nM range. For example, 
lisuride acted as a partial agonist, and amoxipine, clozapine (5) and methiothepin (8) 
acted as antagonists.80 Interestingly, furthermore, 5-HT6 receptors regulate cholinergic 
and glutamatergic neuronal activity (rather than dopaminergic) and have been proposed 
as  regulators of feeding, cognition, emotion, learning, and memory.83 Initial in vivo 
experiments showed that administration of antisense oligonucleotides (AOs), directed at 
5-HT6 receptor mRNA, elicited a behavioral syndrome in rats consisting of yawning, 
stretching, and chewing, which could be dose dependently blocked by the muscarinic 
antagonist atropine.84 This study implies that 5-HT6 receptors modulate cholinergic 
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neurotransmission and, hence, that 5-HT6 receptor antagonists may be useful for the 
treatment of memory dysfunction. In addition, treatment with AOs significantly inhibited 
the increase in 5-HT release from the prefrontal cortex produced by conditioned fear 
stress, suggesting that 5-HT6 receptors may be involved in certain anxiety disorders.85                                     
    
3.7 5-HT6-selective agents: 
    Ligands displaying selectivity for 5-HT6 receptors have become available in increasing 
numbers only very recently. With an intent to understand structure-affinity relationships 
(SAFIR), our laboratory developed some of the very first ligands and has continued to 
identify analogs based on tryptamine as a design template that display a high degree of 
binding affinity and  selectivity for h5-HT6 receptors. It was not until 1998 that the first 
5-HT6-selective antagonists were described: Ro 04-6790 (3b) and Ro 63-0563 (3a) 
(Figure 5) (h5-HT6 Ki = 55 and 12 nM, respectively).86 This prompted others to quickly 
report their efforts in this area. Shortly thereafter, compounds (10) (Figure 5),87 and MS-
245 (14a) (Figure 7)88 were described. Interestingly, although they represented 
independent discoveries, all were identified by random screening methods and all four 
possessed a sulfonamide moiety. The first nonsulfonamide showing 5-HT6 antagonist 
character was 5-methoxy-2-phenyl-N,N-dimethyltryptamine (PMDT; 15).88 Compound 
3b displayed >100-fold selectivity for [3H]-LSD-labeled 5-HT6 receptors over other 5-HT 
receptors and lacked measurable affinity for 23 other receptor populations, whereas 3a 
showed >100-fold selectivity over a total of 69 other receptor/binding sites. Both behaved 
as competitive antagonists of 5-HT-induced cAMP accumulation (pA2 = 6.75 and 7.10, 
respectively) and lacked agonist or inverse agonist actions. One problem associated with 
some of these early antagonists was their low penetration of the CNS.89
21 
    Particularly germane to the present discussion is the binding of tryptamine derivatives 
at 5-HT6 receptors. What follows is an historical narrative of their development. Various 
indolealkylamines, including the tryptamines, bind with high affinity at 5-HT6 receptors. 
However, these analogs typically bind at different populations of 5-HT receptors with 
little selectivity.91 It has been demonstrated, however, that with appropriate molecular 
modification tryptamine derivatives can be developed that display enhanced selectivity 
for different populations of 5-HT receptors.91 This prompted investigation by exploring 
the structure-affinity relationships for the binding of tryptamines at 5-HT6 receptors. In 
1999 Glennon et al.92 (pioneer of the first indole-based structures, starting from the 
endogenous ligand 5-HT) reported the results of such an investigation. A summary of the 
results is shown in Figure 6.78 It was found that O-methylation of 5-HT (1: Ki = 75 nM) 
to 5-methoxytryptamine (9, Ki = 88 nM) had little effect on affinity and that removal of 
the hydroxyl group to give tryptamine (12: Ki = 180 nM) only halved affinity.92 Most 
other changes led to significant decreases in affinity. For example, lengthening the alkyl 
chain by one methylene unit, conformational restriction of the side chain as a 1,2,3,4-
tetrahydropyrido[3,4-b]indole, replacement of the indolic nitrogen atom with an sp3-
hybridized carbon atom, and quaternization of the terminal amine all resulted in a 
dramatic reduction in affinity (i.e., Ki >5000 nM). On the other hand, N-monomethylation 
and N,N-dimethylation resulted in retention or a slight increase in affinity.88
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Figure 6. Influence of structural modification of the binding of 5-HT and simple tryptamines at 5-HT6 
receptors.78 (1) Small alkyl substituents (e.g., methyl, ethyl, n-propyl) at the N1-position dramatically 
decrease affinity but N1-benzyl and N-SO2Ph enhance affinity. (2) A methyl group is tolerated at the 2-
position, as an ethyl group and a phenyl group. (3) An ergoline-like extended conformation seems preferred 
for the binding of N1-unsubstituted tryptamines, and introduction of an α-methyl group decreases affinity. 
(4) N-monomethyl and N,N-dimethyl substitution slightly increase affinity, N,N-diethyl substitution is 
tolerated, N,N-di-n-propyl substitution decreases affinity, and quaternization dramatically decreases 
affinity. (5) Replacement of the 5-hydroxy group of 5-HT with –H halves affinity, whereas the O-methyl 
and O-benzyl ethers retain affinity. Of the four possible methoxy derivatives, affinity decreases as 
5>4>6>7, and replacement of 5-OCH3 by 5-SCH3 enhances affinity. (6) Conversion to an indane abolishes 
affinity. N1-Benzenesulfonyltryptamine derivatives do not necessarily follow this same SAFIR. 
 
    One of the more interesting findings from this study was that 5-HT6 receptors tolerated 
an indolic 2-methyl substituent. Until that time, 2-methyl 5-HT (11) had been considered 
a 5-HT3-selective agonist. Compound 11 was shown to bind at 5-HT6 receptors (Ki = 46 
nM) with 20 times the affinity it displayed for 5-HT3 receptors. Taking advantage of the 
finding that 5-HT3 receptors do not tolerate a 5-methoxy group on the tryptamine ring, 11 
was O-methylated to afford a more selective agent (i.e., 5-methoxy-2-methyltryptamine; 
5-HT6 Ki = 80 nM and 5-HT3 Ki >10,000 nM). Subsequent studies showed that other 
substituents were tolerated at the 2-position, including an ethyl group (EMDT; Ki = 16 
nM; agonist) and a phenyl group (PMDT; Ki = 20 nM; antagonist).88 During the synthesis 
of some of these analogs, N1-benzenesulfonyl derivatives were prepared to protect the 
indolic nitrogen atom as the 2-position substituents were being elaborated. Random 
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screening of one of these intermediates, BS/5-OMe DMT (MS-245, 14a; Ki = 2.3) 
(Figure 7), revealed that it displayed high affinity for 5-HT6 receptors, and a higher 
affinity than that of 5-HT (1; Ki = 78 nM) itself, although it had been shown that 
substitution at the tryptamine N1-position by small alkyl groups resulted in decreased 
affinity.88,92 Subsequently 14a was shown to act as a 5-HT6 receptor antagonist (pA2 = 
8.88).93  
     In a continued effort to identify selective ligands for 5-HT6 receptors, other selective 
(sulfonamide-type) ligands were later reported. These included ALX1175 (17) and 
ALX1161 (18), discovered by the research team of Allelix/NPS Pharmaceuticals during a 
collaboration with Glennon.94 Compound 16 (SB-271046) (Figure 5) was obtained from 
further SAR studies with 10; it was shown to be a potent, selective, and orally 
bioavailable 5-HT6 receptor antagonist.87  
 
   
N
H3C
CH3
N
S O
O
MeO
    
N
H
N
H3C
CH3
MeO
        
N
H
N
H3C
CH3
MeO
      
      MS-245 (14a)                         PMDT (15)                             19                                                
24 
       
N
Me
N
S O
O
F
                  
N
S O
O
Cl
N CH3
H
           
MeO
N
N
H3C
CH3
 
     ALX1175 (17)                        ALX1161 (18)                                   20 
Figure 7. Some representative tryptamine-related 5-HT6 receptor ligands. 
           
    Further studies were done to investigate the role of the benzenesulfonyl group. 
Specificaly, the benzenesulfonyl –SO2– moiety of 14a was replaced by a methylene 
group, a carbonyl group (i.e., 21 and 22 respectively), or was eliminated (i.e., 20) to 
determine its necessity for, and impact on, 5-HT6 receptor binding. Several other aryl-
substituted and indole-substituted analogs were also investigated.95 The binding of 19 and 
14a at 5-HT6 receptors (Table 2) was re-examined and their affinities (Ki = 77 nM and 
2.1 nM, respectively) were nearly identical with what had been previously reported.88,93 
The affinity of the N1-benzyl analog 21 (Ki = 6.5 nM) was about a third that of 14a, 
whereas the affinities of the benzoyl derivative 22 (Ki = 18 nM) and N1-phenyl derivative 
20 (Ki = 33 nM) were about 10- to 15-fold lower than 14a. Nevertheless, all three 
compounds (i,e., 20, 21, 22) displayed higher affinity than their N1-unsubstituted parent 
19. Although optimal among the substituents examined, it would seem that the 
benzenesulfonyl –SO2– moiety is not a requirement for binding, and that the 
benzenesulfonyl group of 14a can be replaced by a benzyl, benzoyl, or phenyl group.95
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Table 2. 5-HT6 receptor affinities of some simple N1-substituted derivatives.95
 
                                            
N
N
H3C
CH3
MeO
R1  
 
 
                                                               R1                              Ki, nM 
                         19                                    -H                              77 
                         14a                      –SO2Phenyl                             2.1 
                         20                        –Phenyl                                 33 
                         21                        –CH2Phenyl                            6.5 
                         22                        –C(=O)Phenyl                      18 
 
Introduction (Table 3) of an electron withdrawing 4-chloro group (i.e., 23) or electron-
donating methoxy substituent (i.e., 24 and 25) had little effect on 5-HT6 receptor affinity. 
Replacement of the N1-benzenesulfonyl group with sterically larger 2-
naphthalenesulfonyl (i.e., 26) or 1-naphthalenesulfonyl (i.e., 27) groups also had little  
effect. The affinities of these derivatives were not more than four times greater than, or 
less than, that of 14a.93
 
 
 
 
 
 
 
26 
Table 3. 5-HT6 serotonin receptor binding of N1-(arylsulfonyl)-N,N-dimethyltryptamine 
               derivatives.93
                                                 
N
H3C
CH3
N
S
R
O
O
MeO
 
 
                                                         R                                      Ki (nM)             
                       14a                            Ph                                     2.3 
                       23                         4-Cl Ph                                  3.1 
                       24                        4-OMe Ph                               8.0 
                       25                    2, 5-diOMe Ph                            1.3 
                       26                        2-Naphthyl                              1.6 
                       27                        1-Naphthyl                              0.9 
 
    The conformationally constrained tryptamine 28 (Ki = 168 nM) (Figure 8) binds with 
modest affinity at 5-HT6 receptors.92 Here too, incorporation of an N1-benzenesulfonyl 
substituent resulted in a dramatic increase in affinity (29; Ki = 1.5 nM).95 Interestingly, 
unlike what was seen in the tryptamine series, the N1-benzyl analogue 30 (Ki = 136 nM) 
did not display enhanced affinity.95
 
 
27 
 
N
H
N CH3
H3C
MeO
               
MeO
N
S O
O
N
H3C
CH3
         
MeO
N
CH2
N
H3C
CH3
 
               28                                             29                                           30 
 
N
H3C
CH3
N
S O
O
                       
N CH3
H3C
N
S O
O
HO
                
N
H3C
CH3
N
                                             
               31a                                           32                                             33a 
Figure 8. Representative 5-HT6 receptor ligands. 
 
Replacement of the 5-methoxy group of 14a (Ki = 2.3 nM) with hydrogen had little 
impact on affinity (i.e., 31a; Ki = 4.1 nM) (Figure 8) and O-demethylation to the 
hydroxyl analog 32 (Ki = 28 nM) decreased affinity by about 10-fold.96 Russell et al.97 
later reported similar results for 31a (Ki = 2.9 nM). Apparently, the 5-methoxy group is 
not a major contributor to binding.97 Further pharmacophoric studies have revealed that 
the benzenesulfonyl moiety of 31a can be replaced by a benzyl group (33a; Ki = 6 nM) 
with retention of antagonist action at 5-HT6 receptors.78 Pullagurla et al.,96 in a further 
investigation, examined closely the terminal amine portion of 14a (Table 4), and the 
aminoethyl group in particular (Figure 9), to determine their influence on 5-HT6 receptor 
binding. With respect to the terminal amine, the secondary amine 34 (Ki = 23 nM) was 
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found to bind with 10-fold lower affinity than its parent, 14a. The N,N-dimethyl 
substituents of 14a could be homologated to N,N-diethyl (35; Ki = 6.2 nM) with little 
effect on affinity; however, incorporation of a bulkier benzyl group, as in 36 (Ki = 43 
nM), decreased affinity by about 20-fold.96  
 
Table 4. 5-HT6 receptor binding of benzenesulfonyltryptamine analogs.96
                                                      
N
R
R'
N
S O
O
Z
X
 
  
                     X                        R                      R'               Z               Ki (nM) 
14a            –OCH3              –CH3               –CH3             –H                 2.3 
34              –OCH3              –CH3               –H                 –H               23 
35              –OCH3              –C2H5             –C2H5            –H                 6.2 
36              –OCH3              –CH3               –CH2Ph         –H               43 
39              –OCH3              –CH3               –CH3             –NH2             2.0 
40              –OCH3              –C2H5             –C2H5            –NHAc      230 
41              –OCH3              –C2H5             –C2H5             –NH2            0.6 
42              –H                      –CH3               –CH3             –NHAc       27 
31b            –H                      –CH3               –CH3             –NH2            0.8 
43              –H                      –C2H5             –C2H5            –NHAc       90 
44              –H                      –C2H5             –C2H5            –NH2            0.6 
45              –OCH3               –CH3               –CH2Ph         –NH2            3.0 
46              –OCH3               –CH3               –CH3             –NHAc       34 
 
29 
    The alkyl chain separating the terminal amine from the indole nucleus was shortened 
by a methylene group. Typically, such chain shortening in tryptamine analogs is not well 
tolerated by serotonin receptors.62 However in this investigation, the chain-shortened 
analog 37a (Ki = 3.1 nM) retained high affinity as compared to its tryptamine counterpart 
31a.   
 
                                                  
N
CH3
N
S O
O
Z
H3C
          
CH3
N
S O
O
Z  
                                                  37a Z = –H             38a Z = –H 
                                                  37b Z = –NH2         38b Z = –NH2 
 
Figure 9. Structures of N1-benzenesulfonylgramines 37 and N1-benzenesulfonylskatol- 
                 es 38.96
 
    The obvious question at this point was whether or not the amine was required for 
binding. Removal of the amine of 37a would result in skatole analog 38a, a compound 
that lacks aqueous solubility. Hence, in order to examine the need for an aminoalkyl 
group at the indole 3-position, it was necessary to locate a position on the molecule that 
would tolerate a solubilizing group. An amino group was selected because a water-
soluble salt could be formed. Several aryl amine derivatives of 14a, 31a, and 35 were 
examined to determine if the amine would be tolerated. Compound 39 (Ki = 2.0 nM), the 
4'-amino analog of 14a, was found to bind with the same affinity as its parent, 14a 
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(Table 4). Likewise, the affinities of amino analogs 41, 31b, and 44 (Ki = 0.6, 0.8, and 
0.6 nM, respectively) are also quite high and indicate that an amino group is tolerated at 
this position.  
    In compound 45 (Ki = 3.0 nM), the presence of the amino group actually increased 
affinity by nearly 15-fold relative to its parent, 36. Furthermore, the affinity of 31b and 
44 again indicate that the presence of a 5-methoxy group is not required for binding. The 
lower affinities of the corresponding acetamido derivatives 40, 42, 43, and 46 show that 
affinity is not directly related simply to the presence of an NH substituent on the aryl 
ring. As a further test of the tolerance of the para amino substituent, compound 37b was 
examined. The affinity of 37b (Ki = 6.9 nM) was similar to that of 37a.96
    On the basis that a para amino group is tolerated by 5-HT6 receptors, compound 38b 
was examined. Compound 38b (Ki = 12 nM) retained affinity for 5-HT6 receptors. Even 
though its affinity is about 3-fold lower than tryptamine derivative 31a, it, like 37, 
represented a novel type of 5-HT6 receptors ligand. 
     Various tryptamimes lacking an N1 substituent generally bind with reduced affinity 
and, like 5-hydroxytryptamine (i.e., serotonin; Ki ca. 100 nM), can display agonist 
character.62 On the basis of comparative structure-affinity and receptor modeling studies, 
93,98 Abate et al.99 proposed that tryptamine analogs, although likely utilizing a common 
aspartate moiety, bind at 5-HT6 receptors differently depending upon whether or not they 
possess an N1 (e.g., a benzenesulfonyl or benzyl) substituent. If the presence or absence 
of an N1 substituent dictates how tryptamine analogs interact with 5-HT6 receptors, it was  
reasoned that chiral analogs of N1-unsubstituted tryptamines might bind differently than 
N1-substituted tryptamines and that isomeric comparisons could prove to be informative. 
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In an extreme case, optical isomers of N1-substituted tryptamines might even display 
opposite enantioselectivity for binding, as compared to their corresponding N1-
unsubstituted counterparts. Introduction of substituents α to the terminal amine of 
tryptamine analogs (e.g. an α-methyl or α-ethyl group) to create a chiral center has been 
shown to result in somewhat reduced 5-HT6 receptor affinity.92 Nevertheless, it was 
thought that reduced affinity might be an acceptable trade-off if it allowed enantiomeric 
potency comparisons to be made. Rather than examining isomers of α-methyl- or α-
ethyltryptamines, however, Abate et al.99 opted to examine their cognate 
pyrrolidinylmethylindole counterparts. That is, because necessary optically active 
configurationally-defined starting materials were readily available, and because 
pyrrolidinylmethylindoles had been previously shown to bind at other (i.e., 5-HT1) 
serotonin receptor populations,100 compounds 47-50 were targeted for examination. 
Isomers of 47 (where R = H or Me) were prepared for binding comparisons with their N1-
unsubstituted analogs 48. To evaluate this hypothesis further, isomers of isotryptamine 49 
were compared with their (C3) unsubstituted counterparts 50. The binding data are shown 
in Table 5. 
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Table 5. Binding affinities for h5-HT6 receptor ligands.99
                               
N
R'
N R
H
        
N
R'
N CH3
H
       
N
N CH3
H3C
   
                                   47, 48                     49, 50                       51 
 
                           R                        R'                   Isomer           Ki (nM) 
48a                    H                    H                            S(+)              2400 
48b                    H                    H                            R(–)                  60 
47a                    H                    SO2Ph                    S(+)                  46 
47b                    H                    SO2Ph                    R(–)                   7.8 
48c                   Me                   H                            S(–)               640 
48d                   Me                   H                           R(+)                    9.1 
47c                   Me                   SO2Ph                    S(–)                    1.7 
47d                   Me                   SO2Ph                   R(+)                    0.3 
50a                    –                     H                           S(+)               8750 
50b                   –                      H                           R(–)                550 
49a                   –                      CH2Ph                   S(+)                  29 
49b                   –                      CH2Ph                   R(–)                   9.9 
51                     –                           –                         –                    32 
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   As with structurally simpler N,N-dialkyltryptamines,62 introduction of an N1-
benzenesulfonyl moiety led to enhanced affinity (comparing pyrrolinylmethylindoles 47a 
with 48a, 47b with 48b, 47c with 48c, and 47d with 48d) (Table 5). Likewise, in the 
isotryptamine series, benzyl analogs 49a and 49b displayed affinity higher than those of 
their parents, 50a and 50b, respectively. In fact, the pyrrolidinylmethylindoles bind with 
affinities higher than those of their simpler N,N-dimethyltryptamine counterparts; for 
example, compound 47d binds with more than 10 times the affinity of 31a and 49b binds 
with 3 times the affinity of 51. Furthermore, it was shown that R-
pyrrolidinylmethylindoles bind with higher affinity than their S-enantiomers and that 47b 
(Ki = 0.3 nM) was found to bind with nearly 10-fold higher affinity than MS-245 (14a). 
Compound 47d was described to be an antagonist, and found to bind at 5-HT6 receptors 
with a Ki <10 nM.101 Although these results could not be used as evidence for different 
modes of binding, they were not inconsistent with the concept that N1-substituted 
tryptamine-related analogs might bind differently than their N1-unsubstituted 
counterparts. These results further identified R-pyrrolidinylmethylindole analogs of MS-
245 (14a) as binding with higher affinity than their S-enantiomers.99
     In continuing efforts by Kolanos et al.102 to identify a binding pharmacophore for MS-
245-type compounds at h5-HT6 receptors, a question of interest was whether an indolic 
N1 nitrogen atom is required for high-affinity binding of tryptamine-related compounds. 
Two strategies were employed to address this issue. First, because isotryptamines have 
been shown to mimic tryptamines at certain 5-HT receptors,103,104 an isotryptamine 
analog of 21 (i.e., 51) was examined. Second, the indole nitrogen atom of 21 was 
replaced by an sp2-hybridized carbon atom to afford indene analog 52. It was reasoned 
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that the sp2-hybridized carbon atom to which the ‘benzyl’ substituent would be attached, 
both in the isotryptamine and indene series, might mimic the electronic character of the 
indole nitrogen atom of 21. Because 38b retains affinity for 5-HT6 receptors, abbreviated 
structures such as 53 were also evaluated. 
 
   
N CH3
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N CH3
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Figure 10.  Some representative atypical 5-HT6 receptor ligands.102
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    Isotryptamines 51 (Ki = 32 nM) and 54 (Ki = 50 nM) were found to bind with high 
affinity, but with lower affinity than N1-benzyltryptamine 21 (Ki = 6.5 nM). Four 
explanations are possible for this somewhat lower affinity: (a) compounds 51 and 54 lack 
a 5-methoxy group, (b) the double bond is in the ‘wrong’ position, (c) relocation of the 
ring nitrogen atom is not well tolerated, and/or (d) the tryptamine N1-nitrogen atom is 
optimal for binding. The des-methoxy analog of 21 (i.e., 33a, Ki = 6 nM) retained affinity 
arguing that the methoxy group is not a major contributor to binding. Benzylindene 52 
(Ki = 57 nM), which lacks the indole nitrogen atom, was found to bind with an affinity 
similar to that of 51 suggesting that an N1 indolic nitrogen atom might not be required. 
However, with 52 there is an additional complicating factor. Although the presence of the 
sp2-hybridized ring carbon atom of 52 might electronically mimic the tryptamine nitrogen 
atom, it also imposes conformational constraint that could ‘lock’ the substituent into a 
conformation that is not particularly favored for binding. Consequently, benzylindene 55 
was examined. The enhanced affinity of 55 (Ki = 3.0 nM) indicated that sp2-hybridized 
ring carbon atom is not required for binding. Indeed racemic 55 (Figure 10) binds with 
an affinity between that of MS-245 (14a) and N1-benzyltryptamine 21. These results 
suggest that neither the tryptamine N1-nitrogen atom, nor an sp2-hybridized carbon atom, 
is essential at this position for binding to 5-HT6 receptors. 
    Apparently, an intact tryptamine moiety is not required for the binding of 39; that is, 
the abbreviated tryptamine 38b (Ki = 12 nM) binds with only 6-fold reduced affinity. The 
abbreviated isotryptamine 56 (Ki = 2530 nM), however, was found to bind with 50-fold 
lower affinity than isotryptamine 54 (Ki = 50 nM). Indene 53 (Ki = 640 nM) also binds 
with low affinity; again, this might be partly attributable to conformational constraint 
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imposed by the exocyclic double bond. But, its reduced counterpart 1-(4-
aminobenzyl)indene (57, Ki = 4470 nM) binds with even lower affinity. These results 
indicate that in the abbreviated series the indolic nitrogen atom or benzenesulfonyl group 
of 38b might contribute to binding. The low affinity of 3-(4-aminobenzyl)indene (58, Ki 
= 11,800 nM) provides evidence that the location of ring unsaturation can also influence 
affinity. Furthermore, the nearly 10-fold higher affinity of 59 (Ki = 740 nM) (the indane 
counterpart of 61) relative to 60 (Ki = 6100 nM) argues that in the abbreviated series, the 
benzenesulfonyl moiety might contribute to binding.102
    In summary then, arylsulfonyltryptamines, such as the benzenesulfonyltryptamine MS-
245 (14a) and compound 31a, were developed in our laboratories as some of the first 
examples of 5-HT6 receptor antagonists. Structure-activity and structure-affinity studies 
have been conducted to identify what structural features of such compounds influence 
functional activity and receptor affinity. Today, the arylsulfonyltryptamines are 
considered a prototypical example of 5-HT6 receptor antagonists. 
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                                     III. Specific aims and rationale                                              
 
    As discussed earlier in the historical narrative, simple tryptamine derivatives bind at 5-
HT6 receptors with modest affinity and ordinarily do so with little to no selectivity.91 We 
have also discussed that introduction of an N1-arylsulfonyl substitiuent to the tryptamine 
nucleus can result in substantially (10- to > 100-fold) enhanced affinity. For example, the 
affinity of 5-OMe DMT (19; Ki = 16 nM) is enhanced upon introduction of an N1-
benzenesulfonyl group (MS-245, 14a, Ki = 2.1 nM), as is that of carbazole 28 (Ki = 168 
nM) to 29 (Ki = 1.5 nM).93,95,103 Furthermore, these benzenesulfonyl-substituted 
tryptamine analogs (e.g., 14a and 29) behaved as 5-HT6 receptor antagonists.93,95 On the 
basis of radioligand binding and modeling studies of the receptor, it has been suggested 
that simple N1-unsubstituted tryptamines might bind differently at 5-HT6 receptors.93,98 
Kolanos et al.105 empirically addressed this issue. 
    It is commonly thought, when two series of agents are binding in a similar manner, that 
parallel structural changes between the two series will typically result in parallel affinity 
shifts. In this investigation Kolanos et al.105 compared the h5-HT6 receptor affinities of 28 
(i.e., 14 pairs of) N1-unsubstituted tryptamines and their N1-benzenesulfonyl-substituted 
counterparts to determine if such is the case. If the affinities of the two series parallel one 
another, this might be taken as evidence that two series are binding somewhat similarly at 
the 5-HT6 receptors. A summary of the binding data is shown in Table 6.105  
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Table 6.  Affinities of some ligands at h5-HT6 receptors.105
                                                  
N
N
R1
R2
R3
Z
X
4
5
6
7          
 
Compound      X                         R1          R2           R3           h5-HT6                Ki (nM) 
                                                                                              b: Z = H            a: Z = SO2Ph                                 
31                    H                         Me         Me           H                 -                 4.1  
62                    H                          Et           Et            H               575               - 
63                    H                          Et           Et            H                 -              14 
64                  4-OMe                   Me         Me           H              154               - 
65                  4-OMe                   Me         Me           H                 -              11 
14                  5-OMe                   Me         Me           H                 -*              2.1 
66                  5-OMe                   Et           Et             H                48              6.2 
67                  5-OMe                   Me         Bn            H              106               - 
68                  5-OMe                  Me          Bn            H                 -             43 
69                  5-OMe                  Me          Me           Et               52              5.5 
70                  5-OMe                  Me          Me           nPr           185              2.5 
71                  5-OCH2Ph            Me          Me            H               18            14 
72                  5-O(CH2)5Ph        Me          Me            H                 6.3         17 
73                  5-SO3CF3             Me          Me            H             220              2.3 
74                  6-OMe                  Me          Me           H           8000              - 
75                  6-OMe                  Me          Me           H               -               15          
76                  7-OMe                  Me          Me           H         19600             - 
77                  7-OMe                  Me          Me           H               -             138 
82                   H                          Me          Me           H               30            - 
* This is compound 19 (Ki = 13 nM). 
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    In the comparative analysis utilizing 14 pairs of tryptamines, it was found that there 
was little correspondence (r2 = 0.201; Figure 11) between the 5-HT6 receptor affinities of 
the examined pairs. The results of this investigation (on compounds with Ki values 
spanning a >10,000-fold range) support the prior suggestion93 that N1-unsubstituted and 
N1-benzenesulfonyl-substituted tryptamines are probably binding (i.e., orienting) in a 
dissimilar fashion upon interaction with 5-HT6 receptors.105
                     
                   
Figure 11. Relationship between the 5-HT6 receptor affinities (pKi values) of 14 N1-
unsubstituted tryptamines and their corresponding N1-benzenesulfonyl counterparts (r2 = 
0.201).105
 
    As already discussed is that the N1-arylsulfonyltryptamine MS-245 (14a; Ki = 2.1 nM) 
binds with a similar affinity as its des-methoxy counterpart 31a (Ki = 4.1 nM). Despite 
structure-affinity studies by our group,78 and others,98,106 a number of questions remain 
unanswered. For example, a structural feature common to the arylsulfonyltryptamines is 
an “aryl” moiety. Yet it has not been established that an aryl group is essential for 
binding. That is, if the aryl group binds at the receptor via a hydrophobic type of 
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interaction, its replacement by an alkyl group of similar or greater hydrophobicity could 
result in retention of affinity. Another feature that has not been fully explored is the 
necessity of the sulfonyl group. It is generally thought that the sulfonamide portion of 
MS-245 (14a) and 31a is important for binding; yet, replacement of the sulfonyl group of 
MS-245 (14a) by a methylene group (i.e., 21 ) has little impact on 5-HT6 receptor affinity 
(see Table 2). 
 
                    
N
H3C
CH3
R
N
S O
O
   
N
H3C
CH3
N
CH2
MeO
    
N
N
H3C
CH3
CH2
R  
                     14a,  R = OCH3                         21                          33a,  R = H 
                     31a,  R = H 
 
    This would argue that the SO2 moiety of MS-245 (14a) plays little, if any, role in 
binding. However, very few examples of N1-benzyltryptamines, such as 21 (Ki = 6.5 
nM), have been examined. This has prompted us to pose the following questions: (1) Is 
an aryl moiety required for high affinity binding at 5-HT6 receptors? (2) Do 
benzyltryptamines, as a class, bind at 5-HT6 receptors (i.e., is the sulfonyl moiety 
important for binding)?  
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A. Specific aims 
1. To determine if the sulfonyl (–SO2–) and aryl moieties of arylsulfonyltryptamines 
are required for high affinity binding at h5-HT6 receptors. 
2. To determine whether the N1-benzenesulfonyl- and their corresponding N1-
benzyltryptamine counterparts bind in a similar fashion. 
 
B. Hypotheses 
1. If the aryl moiety interacts with receptor features via a hydrophobic 
interaction, it should be possible to replace this moiety with other 
hydrophobic groups. 
2. If the sulfonyl moiety of arylsulfonyltryptamines is not required for binding, 
it should be possible to replace this group with a methylene group with 
retention of affinity. 
3. If benzenesulfonyl derivatives (i.e., derivatives of 31) and benzyl derivatives 
(i.e., derivatives of 33) bind in a similar manner, then parallel structural 
changes should result in parallel affinity shifts. 
 
C. Approach 
To determine if the aryl moiety of 31 is required for binding, it is proposed to prepare a 
series of N1-alkylsulfonyltryptamine analogs 78 for comparison with 31. The affinities of 
various 78 analogs will be examined where the π values of the substituents range from 
1.3 to 4.0. (see Table 7). 
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Table 7. Lipophilicities (π values) of substituents to be examined. 
 
                    Substituent                                           Lipophilicity 
                                                                                 (π value)a
                     iPropyl                                                 1.30 
                    nPropyl                                                 1.50 
                    nButyl                                                   2.00 
                    nAmyl                                                   2.50 
                    nOctyl                                                   4.00 
                   Cyclohexyl                                             2.51 
                           aπ values are from Topliss107 relative to π = 2.13 for phenyl. 
 
                          
N
H3C
CH3
N
S
R
O
O          
N
N
H3C
CH3
CH2
R       
N
H3C
CH3
N
S O
O
R      
                                    78                                 33                            31          
                           78a  R = iPr              33a   R = H                 31a   R = H           
                           78b  R = nPr             33b   R = 4-NH2         31b   R = 4-NH2
                           78c  R = nBu            33c   R = 4-OMe         31c   R = 4-OMe 
                           78d  R = nAm           33d  R = 4-CH3          31d   R = 4-CH3  
                           78e  R = nOct           33e   R = 4-CF3          31e    R = 4-CF3
                           78f  R = cC6H11        33f    R = 4-Cl            31f    R = 4-Cl          
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    Very few N1-benzyltryptamines have been examined for their affinity at 5-HT6 
receptors. Those few that have been investigated (i.e., 21 and 33a, Ki = 6.5 nM and 6.0 
nM, respectively) display an affinity comparable to their N1-benzenesulfonyl counterparts 
(i.e., 14a and 31a, Ki = 2.1 nM and 4.1 nM, respectively) and suggest that a sulfonyl 
group might not be important for binding. We propose to examine an extended series of 
N1-benzyltryptamine analogs 33 where R is varied. If the sulfonyl moiety is not required 
for binding, analogs 33 should display affinity comparable to their benzenesulfonyl 
counterparts 31. Several 33 analogs were selected for synthesis and evaluation. In some 
cases, their corresponding benzenesulfonyl counterparts had already been prepared and 
examined in our laboratory. In those instances where this was not the case, the required 
benzenesulfonyl analogs 31 also will be prepared and evaluated. 
    One of the goals of this work is to prepare a series of N1-benzyl- and N1-
benzenesulfonyltryptamine analogs for comparison so that the necessity of the sulfonyl 
function can be determined. If the sulfonyl moiety can be replaced by a methylene group, 
this will indicate that the sulfonyl group is not essential for binding. Furthermore, if the 
sulfonyl group is not required, the benzyltryptamines 33 should bind with an affinity 
similar to their benzenesulfonyl counterparts 31, and there should be a significant 
correlation between the affinities of the two series. Indeed, if such a correlation exists, 
this would indicate that the two series are binding in a similar manner. That is, parallel 
substituent changes in two series of compounds that result in parallel affinity shifts will 
suggest a common mode of binding.95
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    Finally, by examining the effect of substituted benzyl substituents on 5-HT6 receptor 
affinity, it should be possible to determine how (e.g., electronic, lipophilic, steric) 
substituents contribute to 5-HT6 receptor affinity. 
 
D. QSAR (Hansch relationships) 
The concept of QSAR was pioneered by Hansch and co-workers in the 1960s and, hence, 
is referred to as a Hansch relationship.108 The QSAR approach attempts to identify and 
quantify the physicochemical properties of a drug and to see whether one or more 
physicochemical properties of an agent has an effect on the drug’s biological activity.109 
In a broader perspective, QSAR is defined by physicochemical properties (steric, 
electronic, lipophilic, and H-bonding), intrinsic properties (MWt, volume, and surface 
area), and biological properties (IC50, EC50, Ki, and efficacy).110 Thus one of the 
applications of QSAR is lead compound optimization.109 What are these physicochemical 
features which we have mentioned? Essentially they refer to any structural, physical, or 
chemical property of a drug; as mentioned, most commonly studied are lipophilic, 
electronic, and steric properties. This is because it is possible to quantify these effects 
relatively easily. Thus, should the benzyltryptamines bind at 5-HT6 receptors, QSAR 
studies will be performed to identify how various substituents influence affinity. 
 
 E. Selection of benzyl substituents                 
     A very common problem in drug design is to find the optimum substitution on a 
benzene ring or on the benzenoid portion of a fused ring system in an active lead 
compound for maximization of drug potency. Since there are many possible substituents 
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and several different ring positions, the number of possible compounds to consider 
containing up to say two substituents is very large. Thus it would be highly advantageous 
to determine at an early stage which of these compounds might really be worth 
synthesizing. Historically, approaches to this problem have been rather haphazard, 
depending for the most part on the particular experience and intuition of the medicinal 
chemist involved and the relative availability of the starting materials required for 
synthesis.107 However, in the 1960s and 1970s the development of Hansch’s methods for 
structure-activity correlations brought about a more rational approach and the ability to 
generate quantitative structure-activity relationships (QSAR) within analog series.108 
Commonly used property descriptors are a substituent hydrophobicity constant, π, a 
measure of a substituent’s hydrophobicity relative to hydrogen, the Hammett substituent 
constant, σ, a measure of the overall electron withdrawing or donating characteristics of a 
substituent, and Taft’s steric factor, Es. Thus, a limited group of substituents which will 
give a good discrimination between σ, π, and Es can be selected (Figure 12)111 and an 
initial group of compounds synthesized. This procedure is suitable when the compounds 
are relatively easy to synthesize and a considerable lag time is encountered in obtaining 
activity data. However, it is less satisfactory under circumstances where synthesis is more 
difficult and test results are more readily forthcoming.107 
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Figure 12. The Craig plot.112
 
Figure 13. Topliss scheme for aromatic substituents.112 
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    In the context of the foregoing discussion the Topliss operational scheme for aromatic 
substitution may be considered (Figure 13). The assumption is made that the starting 
compound is the unsubstituted phenyl compound and that its biological activity has been 
measured. Since many systems are +π dependent, i.e., activity increases with increasing π 
values, the p-chloro analog is a good first choice, particularly since the ease of synthesis, 
relative to other substituted phenyl compounds, is generally favorable. For the purposes 
of this analysis the potency of the 4-chloro compound can be classified as greater than, 
equal to, or less than the activity of the parent compound. If the potency is increased, this 
can be attributed most probably to a +π effect, or a +σ effect (activity increases with 
increasing σ values), or to the combination of +π and +σ. In this event the 3,4-dichloro 
compound would be selected for synthesis next since this would result in both larger +π 
and  +σ values when summed for the two substituents. Moving to the point where the 
compound has been synthesized and tested, the compound can be classified as more 
potent, equipotent, or less potent than the 4-chloro analog. If potency did increase, then 
the 3-CF3, 4-Cl analog would be the next choice for synthesis since both Σπ and Σσ 
would be larger.107 
     If the 4-chloro compound was found to be equipotent with the parent compound this 
could result from a favorable +π effect offset by an unfavorable –σ dependency. If this is 
the case then the 4-methyl analog should show enhanced potency since this substituent is 
lipophilic and electron releasing, i.e., +π –σ type substituent. Assuming a favorable result 
the next selection would be the 4-C(CH3)3 compound with increased +π and –σ values. In 
the situation where the 4-CH3 compound is equipotent or less potent than the 4-Cl 
compound, it would seem reasonable to assume either an unfavorable steric effect from 
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the para substitution or a –π effect. Since –π effects, i.e., decreasing activity with 
increasing π values are uncommon, the steric explanation seems more probable, hence the 
next move is to 3-Cl in the operational scheme.107
    The remaining segment of the scheme is concerned with the synthetic sequence to be 
followed where the 4-chloro analog was found to be significantly less potent than the 
parent compound. One may conclude that either there is an unfavorable effect from any 
kind of 4-substitution for steric reasons, or activity is –σ or –π controlled. Assuming that 
the –σ effect is the most probable explanation, the 4-methoxy compound ought to be 
favorable selection for synthesis based on the electron releasing property of this 
substituent and its marginally hydrophilic character. Confirmation of this in the form of 
increased activity for the 4-OCH3 compound would lead to the next choice of the 4-
N(CH3)2 analog where there would be an even greater –σ effect. A further trend in the 
right direction would prompt the synthesis of the 3-CH3, 4-N(CH3)2 compound where the 
–σ effect would be further reinforced. Further details on the continuation of the tree are 
contained in the original publication.107
    Ordinarily, the Topliss scheme is employed in an attempt to optimize a particular 
pharmacological activity. That was not the intent here. Rather, the scheme and the Craig 
Plot were use as guides for substituent selection so that representative substituents (i.e., 
substituents with different electronic and hydrophobic character) could be incorporated 
into the target benzyltryptamines. Selection of diverse substituents would also aid 
subsequent QSAR studies by insuring they didn’t have similar physicochemical 
properties. Hence, specific compounds targeted for initial synthesis and evaluation 
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included 33b-f for comparison with 33a. Also targeted were compounds 33g and 33h 
(i.e., 33 where R = 3-chloro and 3,4-dichloro, respectively). 
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                                                IV. Results and Discussion 
 
A. Synthesis 
1. Synthesis of N,N-dimethyltryptamine (DMT) 
The synthesis of all proposed compounds from the previous section was carried out 
starting from the compound DMT (82). DMT was prepared by the Speeter-Anthony 
reaction (Scheme 1).113 According to the reported  procedure, a solution of indole (79) (in 
Et2O/THF) was allowed to react with oxalyl chloride at 0 ˚C and then at room 
temperature to yield compound 80, followed by addition of dimethylamine (aqueous) to 
80, yielding the intermediate 3-indolylglyoxylamide 81. Intermediate 81 was reduced 
with lithium aluminium hydride (LiAlH4) to afford DMT (82) 
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Scheme 1. a) Oxalyl chloride/anhydrous Et2O/THF, 0 ˚C;  b) HN(CH3)2, rt; 
                  c) i. LiAlH4/anhydrous THF, reflux; ii. NaOH, THF (hot).  
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2. Synthesis of N1-benzyltryptamines 
    Starting from N,N-dimethyltryptamine (DMT) (82), two methods were used to 
generate the indolyl anion of compound 82. In one of the procedures, the anion of 
compound 82 was generated by reaction with NaH at 100 ˚C under anhydrous conditions 
(Scheme 2).95 In this reaction a mixture of DMT (82) and NaH was heated until evolution 
of H2 gas ceased. The resultant product was then dissolved in anhydrous DMF resulting 
in a solution at 0 ˚C. This was treated with the appropriately substituted benzyl halide to 
afford the target compounds: analogs of 33 (33c-f, and 33h). Compound 33a had been 
previously reported and was available in our laboratory.95 Compound 33g was 
synthesized adopting the procedure114 where the DMT (82) anion was generated using t-
BuOK in anhydrous THF at room temperature and then allowed to react with the 
corresponding benzyl halide (Scheme 2). This latter procedure for generation of the 
indolyl anion of compound 82 was adopted in an effort to improve yields of target 
compounds; low yields of target compounds were obtained when the former  procedure95 
was used. Attempts to prepare amine analog 33b using a similar approach (i.e., utilizing a 
4-nitro- or 4-acetamido-substituted benzyl halide) were unsuccessful. Subsequently, 
compound 33b was prepared via adopting the procedure116 shown in Scheme 3. In this 
synthetic procedure, the first step was to reduce the 4-nitro group of 83 to an amino 
group. Tin (II) chloride was added to a solution of 83 and then the reaction mixture was 
heated at reflux for 1h. After cooling, the solution was made basic (pH 8-9) and then 
extracted with EtOAc. The organic portion was used in the next reaction without further 
purification. The next step was to protect the 4-amino group of 84. Benzyl bromide was 
added to a suspension of the resultant compound in CH2Cl2 and triethylamine, and the 
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mixture was allowed to stir for 2h followed by purification. The resultant compound 85 
was allowed to react with phosphorus oxychloride in dry DMF in a Vilsmeier type 
reaction to afford 86. Ammonium acetate and MeCN were added to 86 yielding nitro 
olefin derivative 87. The final steps involved reduction of the nitro olefin side chain 
followed by dimethylation and finally deprotection of the 4-amino group to yield the 
target compound 33b. Compounds 33c-h were isolated as their oxalate salts whereas 
compound 33b was isolated as an HCl salt. 
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Scheme 2. a) i. NaH, DMF, 100 ˚C, ii. ArCH2Cl , rt; b) i. t-BuOK, 18-crown-6, THF,  
                      rt;  ii. 3-chlorobenzyl chloride. 
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Scheme 3.116 a) SnCl2·H2O, EtOH; b) BnBr, NEt3, CH2Cl2; c) POCl3/DMF; d) MeNO2,  
                      AcONH4; e)  i. LiAlH4, THF ii. NaBH3CN, H2CO, iii.  Pd/C, MeOH,  
                      HCO2NH4
 
 
3. Synthesis of N1-benzenesulfonyltryptamines 
   Conditions used to synthesize the N1-benzyltryptamines were adopted to synthesize this 
series of compounds. With the exception of compounds 31a95 and 31b96 which had been 
previously reported in our laboratory, compounds 31c-f were synthesized according to 
the procedure where the anion of DMT (82) was generated using t-BuOK in anhydrous 
THF at room temperature and then allowed to react with the appropriate benzenesulfonyl 
chloride (Scheme 4). The reaction mixture was allowed to stir overnight, then extracted 
with EtOAc. The extracts were washed (brine) and dried (Na2SO4), followed by 
evaporating the solvent and then the residue was purified to yield the target compounds 
(31c-f); these compounds were isolated as their oxalate salts. 
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Scheme 4. a) i. t-BuOK, 18-crown-6, THF; ii. ArSO2Cl, rt. 
 
 
4. Synthesis of alkylsulfonyltryptamines 
The two procedures used to synthesize the previous compounds were adopted to 
synthesize the alkylsulfonyltryptamines (Scheme 5). Two of the compounds (i.e., 78d 
and 78f) employed the procedure where the DMT (82) anion was generated using NaH at 
100 ˚C in anhydrous conditions. This was followed by allowing the resultant anion to 
react with their appropriate alkylsulfonyl halides at room temperature. The reaction 
mixture was then extracted with EtOAc and the extracts were washed (brine) and dried 
(Na2SO4). The solvent was evaporated and the residue purified to yield the target 
compound. On the other hand, compounds 78a-c, and 78e were obtained by alkylation 
with the appropriate alkylsulfonyl halides following the generation of the DMT anion 
using t-BuOK in anhydrous THF at room temperature. In separate reactions, for each 
compound, the reaction mixture was extracted with EtOAc and the extracts were washed 
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(brine) and dried (Na2SO4). The solvent was removed and the residue purified to yield the 
target compounds. The target compounds 78a-f were isolated as their oxalate salts.  
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Scheme 5.  a) i. NaH, DMF, 100 ˚C, ii. ArCH2Cl , rt; b) i. t-BuOK, 18-crown-6, THF,  
                      rt;  ii. ArCH2Cl, rt. 
 
   Suitable commercial alkysulfonyl halides for compounds 78d and 78f were not 
available and, hence, required synthesis in our laboratory (Scheme 6117 and Scheme 7;118 
for n-amylsulfonyl chloride (90) and cyclohexylsulfonyl chloride (93), respectively). 
Synthesis of amylsulfonyl chloride was achieved by heating under reflux, amyl sodium 
sulfate (88) in acetone with cyanuric chloride (89) for 20h. The reaction mixture was 
cooled and filtered through a celite pad. The solvent was evaporated from the filtrate then 
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followed by distillation yielding 90. On the other hand, synthesis of cyclohexylsulfonyl 
chloride (93) was achieved by bubbling chlorine gas through a solution of 
cyclohexylthiol (92) in slightly diluted acetic acid maintained at 10-15 °C for 3h. Excess 
chlorine was removed and the resultant mixture was extracted with methylene chloride. 
The methylene chloride extract was washed (NaOH) and then dried (Na2SO4). The 
solvent was removed and then the residue was purified by distillation to yield 93. 
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Scheme 6. a) 18-crown-6, acetone, reflux. 
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                       Scheme 7. a) CH3COOH, H2O, Cl2, rt. 
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B. Radioligand Binding Studies 
Binding studies were conducted by the laboratory of Dr. Bryan Roth (Case Western 
University). In brief, h5-HT6 receptor cDNA was transiently expressed in HEK-293 cells. 
All obtained target compounds were assayed for binding at h5-HT6 receptors with 
[3H]LSD used as the radioligand, and Ki values were determined. The Ki values are the 
result of triplicate determinations. The binding data for compounds are shown in Tables 
8 and Table 9.  
Binding affinities for the alkylsulfonyl compounds 78a-78e ranged from Ki = 135 nM 
for 78c to Ki = 590 nM for 78a (n-butyl and i-propyl, respectively) (Table 8). This is a 
30- to 150-fold lower affinity than that displayed by simple benzenesulfonyltryptamine 
31a (Ki = 4.1 nM). The results show that an arylsulfonyl group at the tryptamine N1-
position is preferred, relative to an alkylsulfonyl group, for 5-HT6 receptor affinity. We 
had proposed that if the aryl moiety interacts with receptor features via a hydrophobic 
interaction, it should be possible to replace this moiety with other hydrophobic groups. 
The alkyl moieties were all hydrophobic; on the contrary, we obtained lower binding 
affinities than expected. Also examined was cyclohexyl analog 78f, which is simply a 
reduced version of 31a, and with even higher hydrophobic character (π = 2.51) relative to 
phenyl (π = 2.13).121 Compound 78f was found to bind with 50-fold lower affinity than 
31a itself. The results suggest that the aryl moiety is optimal for binding, and that the 
interaction of this substituent with the receptor cannot be accounted for simply on the 
basis of hydrophobicity of the sulfonyl substituent. 
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Table 8. 5-HT6 receptor binding affinities of alkylsulfonyltryptamines 78. 
                                               
N
N
H3C
CH3
R       
 
                   Compound         R                           Ki, nM (±SEM )                                                                         
                         78a    -SO2-i-Propyl                           590 (110) 
                         78b    -SO2-n-Propyl                          280 (40) 
                         78c    -SO2-n-Butyl                            135 (20) 
                         78d    -SO2-n-Amyl                            220 (30) 
                         78e    -SO2-n-Octyl                            440 (65) 
                         78f     -SO2-Cyclohexyl                     210 (30) 
 
        The hydrophobicity of a compound can be quantified by using the partition 
coefficient (P). Partition coefficients can be estimated by knowing the contribution that 
various substituents make to hydrophobicity. This contribution is known as the 
substituent hydrophobicity constant (π).119 The substituent hydrophobicity constant is a 
measure of how hydrophobic a substituent is, relative to hydrogen. The value can be 
obtained as follows. Partition coefficients are measured experimentally for a standard 
compound with and without a substituent (X). The hydrophobicity constant (πX) for the 
substituent (X) is then obtained using the following equation. 
                                                 π = log PX – log PH
Where PH is the partition coefficient for the standard compound, and PX is the partition 
coefficient for the standard compound with the substituent. A positive value of π 
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indicates that the substituent is more hydrophobic than hydrogen. A negative value 
indicates that the substituent is less hydrophobic.119
Apart from the fact that the constants would be different, the two factors have different 
emphases. The partition coefficient P is a measure of the drug’s overall hydrophobicity 
and therefore an important measure of how efficiently a drug is transported to its target 
site and bound to its receptor. The π factor is a measure of the hydrophobicity of a 
specific region on the drug’s skeleton. Thus, any hydrophobic bonding to a receptor 
involving that region will be more significant to the equation than the overall transport 
process. If the substituent is involved in hydrophobic binding to a receptor, then the 
QSAR equation using the π factor will emphasize that contribution to biological activity 
more dramatically than the equation using P.119 A phenyl group, such as that found in 31a 
has a π value of 2.13.121 The alkyl substituents used in the present investigation (i.e., 
those found in 78a-78f) possess π values of 1.3 to 4.0 (see Table 7). If the N1 substituent 
of the N1-substituted tryptamines interacts with some receptor feature via a hydrophobic-
type interaction, it should have been possible to replace the phenyl group with a similarly 
hydrophobic group with retention of affinity. The n-butyl and amyl analogs 78c and 78d, 
respectively possess N1-substituents that are nearly as lipophilic as a phenyl group, yet 
their 5-HT6 receptor affinities are substantially reduced relative to 31a. The lipophilicity 
of the cyclohexyl analog (i.e, 78f) is also comparable to that of a phenyl group and it, too, 
binds with reduced affinity. The n-octyl compound bears a group that is even more 
lipophilic than a phenyl group, and it might have been expected that the affinity of 78e 
would have been higher than that of 31a had the receptor interaction involved a simple 
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hydrophobic interaction. Yet, a plot of pKi versus Pi (π) for the seven compounds 78a-
78f and 31a reveals a poor correlation(r = 0.084) (Figure 14). 
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Figure 14.  Relationship between the affinities of 78a-78f and 31a versus π. 
 
 It might be noted that the more hydrophobic n-octyl group is longer than a phenyl 
group and reduced affinity could be rationalized by a less than optimal shape/length of 
the octyl substituent. In an attempt to relate binding affinities of the alkyl substituents to 
their steric effects we plotted pKi versus Es. N1-Methylsulfonyltryptamine has been 
previously reported to bind with Ki = 620 nM.126 We observed that increasing the size of 
the carbon-chain in a branched manner (i.e., i-propyl analog 78a) had little effect on 
affinity. However, the slightly longer n-propyl analog 78b improved binding affinity 2-
fold (78b; Ki = 280 nM). Increased chain length might result in further enhancement of 
affinity. However, the n-butyl and amyl analogs demonstrated comparable binding 
affinities (i.e., Ki = 135 nM and Ki = 220 nM respectively). A plot of pKi versus Es for 
the seven compounds 78a-78f and 31a shows this relationship (Figure 15). The results 
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suggest a high correlation between the binding affinity and bulkiness (size and shape) of 
the substituents (r = 0.947). Since the alkyl side chains are conformationally flexible with 
rotation possible about the C-C bonds, it is not possible to determine the exact 
importance of chain length. Nevertheless, it seems likely that this is an important factor to 
the binding affinity at 5-HT6 receptors. However, we observe (Figure 15) that the data 
points of alphatic substituents are clustered around one area away from the data point of 
the phenyl substituent. The points typically appear like “two” data points. It is generally 
obvious that a line of best fit between two points would give a perfect correlation. Hence, 
this begs for further investigation and verification of this possible relationship. A feasible 
approach would be to select substituents with Es values between the highest Es value of 
the alphatic substituents already tested (Es = -0.79), and phenyl (Es = -2.58). Such 
substituents are for example i-butyl (Es = -0.93), t-butyl (Es = -1.54), and Et2CH (-
1.98).111 If the data points of affinity versus Es of these substituents lie within an 
acceptable range on the line of best fit without greatly disrupting the significant 
relationship (r = 0.947), then it would strongly suggest that there might be a correlation 
between the steric effect and affinity (i.e. increasing steric effect increases affinity). 
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Figure 15.  Relationship between the affinities of 78a-f and 31a versus Es. 
 
To further describe the SAR of alkyl substituents, we considered the influence of 
electronic effects. The Hammett substituent constant (σ) is perhaps the most widely used 
electronic index in QSAR studies of drugs. Hammett correlations express quantitatively 
the relationship between chemical reactivity and the electron-donating or –accepting 
nature of a substituent. The Hammett substituent constant (σ) was originally defined for 
the purpose of quantifying the effect of a substituent on the dissociation constant of 
benzoic acid: 
                                   σX = log KX/KH = log KX – log KH
 
Where KX is the dissociation constant of benzoic acid carrying substituent X; KH is the 
dissociation constant of unsubstituted benzoic acid. 
    Electron attracting substituents (such as –CO2H, -NO2, NR3+) have a positive σ value, 
while electron donating substituents (-OH, -OCH3, -NH2, -CH3) have a negative σ. The 
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value of σ also varies according to whether the substituent is in the meta- or para-position 
of an aromatic ring. Ortho substituents are subject to too many interferences and are not 
used in calculating σ.122
In terms of electronic effect, alkyl substituents ranging from –i-propyl to –octyl do not 
differ much and have similar σ values (-0.13 to -0.16) (Table 9). It is observed from 
Table 9 that the phenyl substituent (σ = -0.01) is electron deficient with little electron 
donating effect compared to moderate electron donating effect demonstrated by alkyl 
substituents. If increasing electronegativity of N1-substituted tryptamines would be 
expected to enhance binding affinity at h5-HT6 receptors, then N1-
alkylsulfonyltryptamines 78 should demonstrate a higher binding affinity than 31a. 
However, we do not observe this relationship. Thus, the electron donating ability of the 
N1-alkyl substituents is probably not involved in the binding of alkylsulfonyltryptamines. 
The higher affinity of 31a over that of the alkyl derivatives suggests that the slightly 
greater electron deficient nature of the phenyl substituent might account for this effect. 
Table 9. Electronegativities (σ values) of alkyl substituents. 
                           Substituent                           Electronegativity 
                                                                        (σ value)b
                            iPropyl                                      -0.15 
                            nPropyl                                     -0.13 
                            nButyl                                       -0.16 
                            nAmyl                                       -0.15 
                            nOctyl                                       -0.16 
                            Cyclohexyl                               -0.15 
                           bσ values are from Hansch et al.121 relative to σ = -0.01 for phenyl. 
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Overall, then, the various N1-alkylsulfonyltryptamines bind at 5-HT6 receptors with 
modest affinity and with affinities substantially lower than that of 31a. Furthermore, their 
affinities which vary over only a very small range, are seemingly unaccounted for by the 
lipophilic, steric, or electronic character of their N1 substituents. 
        Following the aforementioned conclusion, we went a step further to determine if the 
sulfonyl moiety of the arylsulfonyltryptamines is required for binding at h5-HT6 
receptors. López-Rodríguez et al.120 have proposed a pharmacophore model for 5-HT6 
receptors suggesting that a sulfonyl or a sulfonamide moiety is a common 
pharmacophoric element of most ligands that interact with amino acids in the 
transmembrane domain of the 5-HT6 receptors. However, as has already been mentioned, 
our laboratory had previously shown that the unsubstituted benzenesulfonyl analog 31a 
and its unsubstituted benzyl counterpart 33a bind with comparable affinities at h5-HT6 
receptors (Ki = 4.1 nM and Ki = 6.0 nM) respectively.93,95 Thus, while a sulfonyl moiety 
might be important for binding, its presence certainly is not required. However, the 
affinities of a series of benzenesulfonyl analogs, and their corresponding benzyl analogs, 
have never been compared. 
To further investigate this concept, we proposed that if the sulfonyl moiety of 
arylsulfonyltryptamines is not required for binding, it should be possible to replace this 
group with a methylene group with retention of affinity. Furthermore, if the two series 
(i.e., benzenesulfonyl and benzyl) bind in the same manner, the two series should show 
comparable binding affinities. In light of this proposal, a small series of N1-benzyl 
analogs 33 was prepared and examined (Table 10). Substituents selected for evaluation 
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included several electron donating and electron withdrawing groups; as mentioned earlier 
we employed the Topliss scheme107 as a guide for substituent selection. 
 
Table 10. 5-HT6 receptor binding affinities of benzenesulfonyltryptamines 31 relative to 
their benzyl counterparts 33. 
                                                 
N
N
H3C
CH3
X
R              
 
                                                      Ki, nM (S.E.M)a
              R              X = SO2 (31)                                             X = CH2 (33) 
a          H                      4.1b                                                        6.0b
b          4-NH2              0.8 (0.4)c                                             44    (7)   
c          4-OMe           13.0 (3)                                                132    (25) 
d          4-Me                2.5 (0.6)                                               29    (3) 
e          4-CF3               1.9 (0.4)                                             445    (50) 
f           4-Cl               94    (25)                                                20    (5) 
g          3-Cl                 –                                                           34    (± 6) 
h          3,4 diCl           –                                                           50    (14) 
 
a S.E.M are not shown for previously reported binding data. 
b Binding data previously reported from our laboratories78,96
c See Table 4. 
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    Initially we prepared 33f and 33c. Compound 33f is the 4-chloro substituted benzyl 
analog; a chloro substituent is considered hydrophobic (+π) and electron withdrawing 
(+σ); details of the Hammett constant (σ) will be discussed later in this section. In 
contrast 33c bears an electron donating methoxy group (-σ, +π). As proposed by the 
Topliss scheme, a high affinity for the chloro analog might be attributed most probably to 
a +π effect, or +σ effect, or the combination of +π and +σ. In this event the 3,4-dichloro 
compound would be selected for synthesis. Because chloro analog 33f (Ki = 20 nM) 
possessed higher affinity than 33c (Ki = 132 nM), we prepared the 3,4-dichloro benzyl 
analog 33h. Compound 33h was found to bind with high affinity (Ki = 50 nM); but, this 
was a slight drop in affinity relative to 33f and contrary to what might be expected. This 
observation prompted us to prepare and examine the 3-chloro benzyl analog 33g. 
Interestingly, compound 33g (Ki = 34 nM) was found to bind with similar binding 
affinity as 33f and 33h; a significant change in affinity was not demonstrated. However, 
since substituents at the 3-position might demonstrate rotameric binding it is confounding 
to explain what influence the 3-chloro substituent has on the binding of N1-benzyl 
analogs at h5-HT6 receptors. Therefore, on examination of the aforementioned series of 
N1-benzyl analogs, only 4-substituted benzyl analogs were examined to reduce any 
potential complications in data interpretation that might arise from possible rotameric 
binding or untoward effects associated with 3-position substituents. 5-HT6 receptor 
affinities of the target compounds ranged from 20 nM to >400 nM (Table 10). But, none 
of the benzyl analogs retained the affinity of the unsubstituted benzyl analog 33a (Ki = 
6.0 nM). 
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One explanation for the reduced affinity of 33b-f, compared with 33a, is that the 
receptor does not tolerate substituents on the benzylic nucleus. This seems unlikely 
because certain analogs of 14a bearing benzenesulfonyl substituents have been 
previously shown to bind with affinities comparable to that of 14a itself.93 However, with 
regard to these latter compounds, each possesses a methoxy group on the indolic ring. In 
order to make a more strict comparison, the benzenesulfonyl counterparts of 33c-f (i.e., 
31c-f) were prepared and examined. The results (Table 10) show that 5-HT6 receptors 
tolerate aryl substituents, and that the 4-amino, 4-methyl, and 4-trifluoromethyl analogs 
31b, 31d, 31e (Ki = 0.8 nM, 2.5 nM, and 1.9 nM, respectively) bind at least as well as 
their unsubstituted parent 31a. The results indicate that even though N1-benzyl-
substituted analogs bind at 5-HT6 receptors, they bind with reduced affinity relative to 
their corresponding N1-benzenesulfonyl counterparts.  
If benzenesulfonyl derivatives (i.e., of 31) and benzyl derivatives (i.e., derivatives of 
33) bind in a similar manner, then parallel structural changes should result in parallel 
affinity shifts. To test this hypothesis, we conducted a correlation analysis between the 
two series of compounds (i.e., derivatives of 31 and derivatives of 33) to determine 
whether their binding affinity data might show a linear relationship. Statistical analysis 
was peformed using the GraphPad Prism program. A comparison of the affinities of the 
series 33 compounds with the series 31 compounds (r = -0.224; n = 6) shows little 
correspondence between the two (Figure 16). The calculated coefficient of 
determination, r2 = 0.050 (i.e., variance), describes further that one of the 2 variables 
explains only 5% of the variation in the other variable. Consequently, these results 
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suggest that the two series of compounds bind in a dissimilar fashion or at least that 
parallel substituent changes result in non-parallel shifts in 5-HT6 receptor affinity. 
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Figure 16. Relationship between the affinities of N1-benzyl- and N1-
benzenesulfonyltryptamine analogs 33 and 31, respectively. 
 
On the examination of the effect of substituted benzyl and benzenesulfonyl 
substituents on 5-HT6 affinity, we have demonstrated dissimilarity in binding affinities. 
That is, substituent alteration results in different binding affinities for the two series. 
Since the substituents exhibit varying physicochemical properties (electronic, lipophilic, 
and steric), this begs the question of what influence these properties might have on the 
binding of 31 and 33 at 5-HT6 receptors. In an effort to answer this question, the inherent 
relationship (if any) between these physicochemical properties and the binding at 5-HT6 
receptors was investigated in a further QSAR study. For this purpose, the influence of the 
parameters in Table 11 were examined. 
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Table 11. Summary of the physicochemical parameters employed.121,123
 
Substituent              σ                      π                      Es                 L (Å)                 W(Å) 
H                           0                   0                           0                    2.06                   1.00 
NH2                     -0.66             -1.23                    -0.61               2.93                   1.50 
OMe                    -0.27             -0.02                    -0.55               3.98                   1.35 
CH3                     -0.17              0.56                     -1.24               3.00                   1.52 
CF3                       0.54               0.88                    -2.4                 3.30                   1.98 
Cl                          0.23               0.71                   -0.97               3.52                   1.80 
 
First considered was molecular “bulk” as an important factor in structure-activity 
relationships.122 Steric substituent constants (Es) derived from Taft’s model, and 
STERIMOL parameters were considered in the present analyses. In order for a drug to 
interact with an enzyme or a receptor, it has to approach, and then interact with a binding 
site. The bulk, size, and shape of the drug may influence this process. For example, a 
bulky substituent may act like a shield and hinder the ideal interaction between drug and 
receptor. Alternatively, a bulky substituent may help to orientate a drug properly for 
maximum receptor binding and increase activity. Quantifying steric properties is more 
difficult than quantifying hydrophobic or electronic properties.109 Several methods have 
been tried and two are described here: 
    Taft’s steric (Es) constants were the first widely used parameters for examining steric 
substituent effects in drug design.123 They were developed in studies of organic reaction 
mechanisms of hydrolysis of aliphatic esters as correlation parameters for intramolecular 
effects of substituents of nearby reaction centers (Figure 17). However, already indicated 
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by Taft and further substantiated by Charton,124 there is a linear correlation between Es 
constants and (minimum) radii of spherical and symmetrical substituents, so that 
evidently Es is a steric constant independent of electronic effects. This was further 
developed by Kutter and Hansch,125 who derived a linear regression equation linking Es 
and the (average) radii of several substituents that had not been determined 
experimentally. For nonsymmetrical substituents, these calculations were based either on 
minimum radii (NH2, OCH3) or on two different radii that resulted in two Es values 
(NO2). 
        
XH2C
O
O
XH2C
O
O
CH3
(-)
k+ H2O + HOCH3
Es = log kXCH2COOMe  -  log  kCH3COOMe  = log kx/ky  
Figure 17.  Ester hydrolysis reaction and equation used to define the Taft steric  
                   parameter, Es.123 
 
    Another approach to measuring the steric factor involves a computer program called 
STERIMOL which calculates steric substituent values (Verloop steric parameters) from 
standard bond angles, van der Waals radii, bond lengths, and possible conformations for 
the substituent.123 This computer program has been devised to simulate the building of 
molecules or molecular groups from the well-known Corey-Pauling-Koltun (C.P.K.) 
atomic models. The partial bond lengths (covalent radii) and the bond angles used for 
defining the bond vectors of the various atom types in the program have been taken from 
the C.P.K. catalog as issued by The Ealing Corporation in the United States. The 
STERIMOL program is capable of giving different types of output with respect to the 
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shape of molecules and substituents.123 It is concluded that a length parameter L for the 
substituents should be used. The minimum width was chosen as the initial width 
parameter BB1, and from this parameter, three additional width parameters B2B , BB3, and B4B  
were derived in such a way that the four B parameters would measure the width in four 
rectangular directions.123 Unlike Es, the Verloop steric parameter can be measured for any 
substituent. For example, the Verloop steric parameter for carboxylic acid group are 
demonstrated in Figure 18. L is the length of the substituent while B1-B4 are the radii of 
the group.119 
 
Figure 18. Schematic representation of dimensions of the benzoic acid substituent.119 
 
Considering the influence of steric factors on the binding of 31 and 33 derivatives at 5-
HT6 receptors,  correlation analysis plots relating N1-benzyl analogs (Figure 19) and N1-
benzenesulfonyl analogs (Figure 20) to Es are shown below. 
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Figure 19. Relationship between the affinities of N1-benzyltryptamine analogs 33 versus 
the Es.  
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Figure 20. Relationship between the affinities of N1-benzenesulfonyltryptamine analogs 
31 versus Es.  
                 
A modest correlation (r = 0.756) is demonstrated between the benzyltryptamines and 
influence of steric effect on the binding at 5-HT6 receptors (Figure 19). Compounds with 
large substituents show low affinity, whereas the compound with the smallest substituent 
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has the highest affinity. These results suggest that the steric effect has an unfavorable 
influence on the binding affinities of benzyltryptamines at serotonin h5-HT6 receptors. 
However, these observations could be coincidential and other possible parameters such 
hydrophobic and/or electronic interactions could be at play. On the other hand, the same 
substituents demonstrate a weaker correlation (r = -0.158) with the binding of 
benzenesulfonyl analogs (Figure 20). These results suggest that the steric effects of the 
4-position substituents on the benzenesulfonyltryptamine analogs demonstrate no 
significant relationship to the binding affinities.  
In a relationship between the affinity of N1-benzyltryptamine analogs and σ (electronic 
substituent constant), there is a weak correlation (r = -0.270; Figure 21). Similarly, that 
of benzenesulfonyltryptamine analogs versus σ also showed a weak correlation (r = -
0.352; Figure 22). The results suggest that the binding affinities of the two series of 
compounds cannot be accounted for solely by the electronic effect of their 4-position 
substituents. 
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Figure 21. Relationship between the affinities of N1-benzyltryptamine analogs 33 versus 
σ . 
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Figure 22. Relationship between the affinities of N1-benzenesulfonyltryptamine analogs 
31 versus σ . 
 
    Comparison of the two series of compounds with π is shown in Figure 23 and 24. 
There was no significant relationship between pKi (N1-benzyltryptamine analogs) and π 
(r = -0.200; Figure 23), whereas the relationship between pKi (N1-
benzenesulfonyltryptamine analogs) and π showed a weak correlation (r = -0.470; Figure 
24). Evidently, these results do not reveal a clear correlation of substituent lipophilicities 
with binding affinities. That is, increasing lipophilicity is not accompanied by increased 
binding affinities in either series.  
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Figure 23. Relationship between the affinities of N1-benzyltryptamine analogs 33 versus 
π. 
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Figure 24. Relationship between the affinities of N1-benzenesulfonyltryptamine analogs 
31 versus π. 
 
   Finally, we considered relationships between binding affinities and the Verloop 
parameters (i.e., length and width). A similar, moderate correlation (r = -0.655) (Figures 
25, and 26 respectively) was obtained for the binding affinity of N1-benzyltryptamine 
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analogs and length (L) and width (W). These results suggest that the binding affinities of 
the N1-benzyltryptamine analogs might be partially attributable to the length and breadth 
of the substituents at the 4-position of the phenyl ring.  
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Figure 25. Relationship between the affinities of N1-benzyltryptamine analogs 33 versus 
length. 
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Figure 26. Relationship between the affinities of N1-benzyltryptamine analogs 33 versus 
width. 
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    On the other hand, a correlation between binding affinities of the N1-
benzenesulfonyltryptamine analogs versus length, and width yielded weak correlations (r 
= -0.447; Figure 27), and (r = -0.122; Figure 28), respectively. No clear relationship is 
demonstrated between length or width and binding the affinities of the N1-
benzenesulfonyltryptamine analogs. Thus, the directional parameters of the substituents 
might not contribute significantly to the changes in the binding affinities of N1-
benzenesulfonyltryptamine analogs at 5-HT6 receptors. 
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Figure 27. Relationship between the affinities of N1-benzenesulfonyltryptamine analogs 
31 versus Length. 
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Figure 28. Relationship between the affinities of N1-benzenesulfonyltryptamine analogs 
31 versus width. 
 
    Overall, none of the individual parameters examined (i.e., steric, electronic, lipophilic 
or Verloop) seemed to account for the binding of N1-benzyl- or N1-
benzenesulfonyltryptamines at 5-HT6 receptors. As already mentioned, sample size was 
small. Furthermore, the range of affinities is limited. There are some indications that 
inclusion of more than one parameter in attempted relating equations might afford more 
meaningful results. However, the small number of compounds available at this time does 
not allow examination of multiple parameters. Additional analogs will need to be 
prepared and examined in order to search for statistically significant relationships using 
multiple parameters.  
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                                                              V. Conclusions 
 
    N1-Arylsulfonyltryptamines represent a class of 5-HT6 receptor antagonists developed 
in our laboratories. One of the goals of the present investigation was to determine if the 
sulfonyl and aryl moieties of arylsulfonyltryptamines are required for high affinity 
binding at h5-HT6 receptors. A series of N1-alkylsulfonyl-, N1-benzyl-, and N1-
benzenesulfonyltryptamine analogs was prepared and examined. 
    A general finding of the present investigation is that replacement of the 
benzenesulfonyl group of MS-245-like (i.e., 14a-like or 31a-like) 
benzenesulfonyltryptamines with an alkylsulfonyl group results in diminished affinity for 
h5-HT6 receptors. The alkylsulfonyl derivatives 78 differed with respect to chain length, 
shape, and hydrophobicity, but none retained the affinity of the simplest MS-245-like 
compound 31a. No clear correlation between the binding affinities of these compounds 
and their physicochemical properties was identified, but, it would seem that π-π 
interactions better account for the binding of N1-substituted tryptamines than do simple 
hydrophobic interactions because of the higher affinity of the arylsulfonyl derivatives. 
   Other goals were to determine if N1-benzyltryptamines bind with high affinity and to 
determine whether the N1-benzenesulfonyl- and their corresponding N1-benzyltryptamine 
counterparts bind in a similar fashion. Upon comparison of their binding affinities, the 
N1-benzyl-substituted compounds 33 were found to bind at 5-HT6 receptors but typically 
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did so with affinities somewhat lower than their benzenesulfonyl counterparts 31. 
Evidence suggests that the two series (i.e., 31 and 33) are probably binding differently 
and, because the only structural difference between the two series is a sulfonyl versus 
methylene group, it would seem that the sulfonyl group determines the manner of 
binding. That is, the presence of the sulfonyl group results in a somewhat higher affinity. 
The phenyl-SO2-N bond angle of N-benzenesulfonylpyrrole (ca. 105-106˚)126 is only 
slightly less than the bond angle of a tetrahedral carbon atom. Furthermore, the N1-S 
bond length (ca. 1.6-1.7 Å) found in such compounds is only slightly longer than the N1-
C bond length (ca. 1.5 Å) of N1-benzylindoles.126-128 So, it is unlikely that geometry plays 
a substantial role in the affinity differences observed between the 
benzenesulfonyltryptamines and their benzyltryptamine counterparts. Thus, although it 
cannot be concluded that the sulfonyl group is essential for binding, it would appear that 
its presence is optimal when similarly-substituted pairs of compounds are examined, and 
that the oxygen atoms might form an anchoring interaction with some receptor-associated 
feature. The results also suggest, if the two series are binding differently, that structure-
affinity findings from the benzenesulfonyl series cannot be extrapolated to the benzyl 
series. Nevertheless, because N1-benzyltryptamines bind at 5-HT6 receptors, additional 
studies will be required to optimize their affinity. 
    The overall findings of the present investigation are as follows: a) N1-
alkylsulfonyltryptamines bind at h5-HT6 receptors with modest affinity lower than that of 
N1-arylsulfonyltryptamines, b) the affinities of the N1-alkylsulfonyltryptamines cannot be 
explained simply on the basis of their hydrophobicity or shape, c) N1-benzyltryptamines 
bind at human 5-HT6 receptors, but do so with somewhat lower affinity than their 
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corresponding N1-benzenesulfonyltryptamines, d) there is no correlation between the 
affinities of the N1-benzyl- and N1-benzenesulfonyltryptamines suggesting that they 
might bind in a different manner, e) the affinities of the N1-benzyl- and N1-
benzesulfonyltryptamines could not be readily explained on the basis of the hydrophobic, 
size, shape, or electronic character of their N1-substituents. It is concluded that an aryl 
moiety is required for high affinity binding, but that a sulfonyl group, while seemingly 
making a contribution, is not essential. As such, we have substantially extended the 
structure-affinity relationships for the binding of the N1-arylsulfonyltryptamines at h5-
HT6 receptors. 
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                                                     VI. Experimentals 
 
A. Chemistry: 
Melting points were determined in a glass capillary on a Thomas Hoover melting point 
apparatus and are uncorrected. Proton nuclear magnetic resonance (1H NMR) spectra 
were obtained on a Varian Gemini 300 MHz spectrometer and the chemical shifts are 
reported in parts per million (δ), using tetramethylsilane (TMS) as an internal standard. 
Elemental analysis was performed by Atlantic Microlab Inc. (Norcross, GA), and 
determined values are within 0.4% of theory (except where indicated). Column 
chromatography was performed on silica gel, grade 62-200 mesh, 150 Å (Sigma-Aldrich, 
MO). Routine thin-layer chromatography (TLC) was performed on silica gel GHLF (250 
Microns, 2.5 x 10 cm; Analtech Inc., Newark, DE). 
N,N-Dimethyl-2-[1-(4-methoxybenzenesulfonyl)-1H-indol-3-yl]-1-aminoethane 
Oxalate (31c) 
 
N,N-Dimethyltryptamine (82) (0.32 g, 1.68 mmol) in dry THF (5 mL) was added in a 
dropwise manner to  a stirred mixture of potassium tert-butoxide (0.25 g, 2.18 mmol) and 
18-crown-6 (0.04 g, 1.68 mmol) in dry THF (10 mL). The reaction mixture was cooled at 
0 °C for 15 min, and then a solution of 4-methoxybenzenesulfonyl chloride (0.52 g, 2.52 
mmol) in dry THF (5 mL) was added in a dropwise manner. The reaction mixture was 
allowed to stir at room temperature overnight, then concentrated and extracted with 
EtOAc (3 x 15 mL), washed with brine (20 mL) and dried (Na2SO4). The solvent was 
evaporated under reduced pressure. The residue was chromatographed on a silica gel 
column using CH2Cl2/MeOH (9.5:0.5) as eluent to give  0.48 g of a brown yellow oil. 
The product was isolated as an oxalate salt to give 31c (0.24 g, 31%) as white crystals 
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after recrystallization from Me2CO: mp 164-164 °C; 1H NMR (DMSO-d6)  δ 2.78 (s, 6H, 
CH3), 3.03 (t, 2H, CH2), 3.30 (t, 2H, CH2), 3.78 (s, 3H, CH3), 7.07 (d, 2H, ArH), 7.25-
7.39 (m, 2H, ArH), 7.66 (d, 1H, ArH), 7.71 (s, 1H, ArH), 7.85 (m, 3H, ArH). Anal. Calcd 
for C19H22N2O3S · C2H2O4: C, 56.23; H, 5.39; N, 6.24 Found: C, 56.05; H, 5.39; N, 6.28. 
 
N,N-Dimethyl-2-[1-(p-toluenesulfonyl)-1H-indol-3-yl]-1-aminoethane Oxalate (31d) 
 
N,N-Dimethyltryptamine (82) (0.32 g, 1.68 mmol) in dry THF (5 mL) was added in a 
dropwise manner to  a stirred mixture of potassium tert-butoxide (0.25 g, 2.18 mmol) and 
18-crown-6 (0.04 g, 1.68 mmol) in dry THF (10 mL). The reaction mixture was cooled at 
0 °C for 15 min, and then a solution of p-toluenesulfonyl chloride (0.48 g, 2.52 mmol) in 
dry THF (5 mL) was added in a dropwise manner. The reaction mixture was allowed to 
stir at room temperature overnight, then concentrated and extracted with EtOAc (3 x 15 
mL), washed with brine (20 mL) and dried (Na2SO4). The solvent was evaporated under 
reduced pressure. The residue was chromatographed on a silica gel column using 
CH2Cl2/MeOH (9.5:0.5) as eluent to give  0.57 g of a brown yellow oil. The product was 
isolated as an oxalate salt to give 31d (0.19 g, 27%) as white crystals after 
recrystallization from Me2CO: mp 191-193 °C; 1H NMR (DMSO-d6)  δ 2.31 (s, 3H, 
CH3), 2.82 (d, 6H, CH3), 3.05 (t, 2H, CH2), 3.35 (d, 2H, CH2), 7.29-7.40 (m, 4H, ArH), 
7.66 (d, 1H, ArH), 7.73 (s, 1H, ArH), 7.83 (d, 2H, ArH), 7.91 (d, 1H, ArH). Anal. Calcd 
for C19H22N2O2S · C2H2O4 · 0.25H2O: C, 58.84; H, 5.49; N, 6.23 Found: C, 57.73; H, 
5.60; N, 6.29.  
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N,N-Dimethyl-2-[1-(4-trifluoromethylbenzenesulfonyl)-1H-indol-3-yl]-1-
aminoethane Oxalate (31e) 
 
N,N-Dimethyltryptamine (82) (0.32 g, 1.68 mmol) in dry THF (5 mL) was added in a 
dropwise manner to  a stirred mixture of potassium tert-butoxide (0.25 g, 2.18 mmol) and 
18-crown-6 (0.04 g, 1.68 mmol) in dry THF (10 mL). The reaction mixture was cooled at 
0 °C for 15 min, and then a solution of 4-(trifluoromethyl)benzenesulfonyl chloride (0.62 
g, 2.52 mmol) in dry THF (5 mL) was added in a dropwise manner. The reaction mixture 
was allowed to stir at room temperature overnight, then concentrated and extracted with 
EtOAc (3 x 15 mL), washed with brine (20 mL) and dried (Na2SO4). The solvent was 
evaporated under reduced pressure. The residue was chromatographed on a silica gel 
column using CH2Cl2/MeOH (9.5:0.5) as eluent to give 0.58 g of a brown yellow oil. The 
product was isolated as an oxalate salt to give 31e (0.32 g, 39%) as white crystals after 
recrystallization from Me2CO: mp 176-179 °C; 1H NMR (DMSO-d6)  δ 2.78 (s, 6H, 
CH3), 3.05 (t, 2H, CH2), 3.31 (t, 2H, CH2), 7.31-7.44 (m, 4H, ArH), 7.69 (d, 1H, ArH), 
7.80 (s, 1H, ArH), 7.98 (t, 2H, ArH), 8.18 (d, 1H, ArH). Anal. Calcd for C19H19F3N2O2S · 
C2H2O4 : C, 51.84; H, 4.35; N, 5.75 Found: C, 51.81; H, 4.35; N, 5.72. 
 
N,N-Dimethyl-2-[1-(4-chlorobenzenesulfonyl)-1H-indol-3-yl]-1-aminoethane Oxalate 
(31f) 
 
N,N-Dimethyltryptamine (82) (0.32 g, 1.68 mmol) in dry THF (5 mL) was added in a 
dropwise manner to  a stirred mixture of potassium tert-butoxide (0.25 g, 2.18 mmol) and 
18-crown-6 (0.04 g, 1.68 mmol) in dry THF (10 mL). The reaction mixture was cooled at 
0 °C for 15 min, and then a solution of 4-chlorobenzenesulfonyl chloride (0.53 g, 2.52 
mmol) in dry THF (5 mL) was added in a dropwise manner. The reaction mixture was 
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allowed to stir at room temperature overnight, then concentrated and extracted with 
EtOAc (3 x 15 mL), washed with brine (20 mL) and dried (Na2SO4). The solvent was 
evaporated under reduced pressure. The residue was chromatographed on a silica gel 
column using CH2Cl2/MeOH (9.5:0.5) as eluent to give 0.36 g of a brown yellow oil. The 
product was isolated as an oxalate salt to give 31f (0.24 g, 31%) as white powder after 
recrystallization from Me2CO: mp 180-182 °C; 1H NMR (DMSO-d6)  δ 2.78 (s, 6H, 
CH3), 3.06 (t, 2H, CH2), 3.29 (t, 2H, CH2), 7.28-7.41 (m, 3H, ArH), 7.66-7.68 (m, 2H, 
ArH), 7.74 (s, 1H, ArH), 7.92-7.99 (m, 3H, ArH). Anal. Calcd for C18H19ClN2O2S · 
C2H2O4 : C, 53.03; H, 4.67; N, 6.18 Found: C, 53.15; H, 4.64; N, 6.21. 
 
N,N-Dimethyl-2-[1-(4-aminobenzyl)-1H-indol-3-yl]-1-aminoethane Hydrochloride 
(33b) 
 
A solution of 87 (0.47 g, 1 mmol) in dry THF (10 mL) was added in a dropwise manner 
to a stirred suspension of LiAlH4 (0.21 g, 5.5 mmol) in dry THF (10 mL) at 0 °C under a 
nitrogen atmosphere. The reaction mixture was heated at reflux for 1.5 h. The excess 
LiAlH4 was destroyed by addition of H2O (0.2 mL), NaOH (15%, 0.2 mL) and H2O (0.6 
mL) at 0 °C. The precipitate was removed by filtration and washed with hot THF (25 
mL). The combined washings and filtrate was dried (Na2SO4) and the solvent was 
evaporated under reduced pressure to give an oily residue. Chromatography on a silica 
gel column (Aldrich silica gel 60) using CH2Cl2/MeOH (9:1) as eluent gave the crude 
product, 2-[1-(4-N,N-dibenzylaminobenzyl)-1H-indol-3-yl]-1-aminoethane (0.28 g, 63%) 
as an oil: 1H NMR (CDCl3) δ 3.03 (t, 2H, CH2), 3.09 (t, 2H, CH2), 4.63 (s, 4H, CH2), 
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5.14 (s, 2H, CH2), 6.65 (d, 2H, ArH), 6.97 (d, 2H, ArH), 6.98 (s, 1H, ArH), 7.09 (t, 1H, 
ArH), 7.17 (t, 1H, ArH), 7.21-7.35 (m, 11H, ArH), 7.60 (d, 1H, ArH). 
A solution of aqueous formaldehyde (38%, 190 μL) was added in a dropwise manner to a 
cooled (ice bath) and stirred mixture of 2-[1-(4-N,N-dibenzylaminobenzyl)-1H-indol-3-
yl]-1-aminoethane (0.27 g, 0.6 mmol), sodium cyanoborohydride (0.08 g, 1.3 mmol), and 
glacial acetic acid (172 μL, 0.3 mmol) in MeOH/MeCN (10/3 mL). The reaction mixture 
was then allowed to warm to room temperature and allowed to stir for 2 h before 
saturated aqueous K2CO3 (5 mL) was added. The solvent was removed under reduced 
pressure. The remaining residue was diluted with H2O (5 mL) and extracted with EtOAc 
(3 x 10 mL). The combined organic portions were washed with brine (1 x 15 mL) and 
dried (Na2SO4), and the solvent was evaporated under reduced pressure. The oily residue 
was chromatographed on a silica gel column (Aldrich silica gel 60) using CH2Cl2/MeOH 
(95:5) as eluent to give the crude product N,N-dimethyl-2-[1-(4-N,N-
dibenzylaminobenzyl)-1H-indol-3-yl]-1-aminoethane (0.18 g, 61%) as a colorless oil: 1H 
NMR (CDCl3) δ 2.53 (s, 6H, CH3), 2.86 (t, 2H, CH2), 3.10 (t, 2H, CH2), 4.65 (s, 4H, 
CH2), 5.15 (s, 2H, CH2), 6.66 (d, 2H, ArH), 6.98 (d, 2H, ArH), 6.98 (s, 1H, ArH), 7.12 (t, 
1H, ArH), 7.20 (t, 1H, ArH), 7.22-7.37 (m, 11H, ArH), 7.61 (d, 1H, ArH). 
Anhydrous ammonium formate (0.11 g, 1.8 mmol) was added in a single portion to a 
stirred suspension of N,N-dimethyl-2-[1-(4-N,N-dibenzylaminobenzyl)-1H-indol-3-yl]-1-
aminoethane (0.17 g, 0.4 mmol) and an equal weight of Pd/C (10%, 0.17 g) in anhydrous 
MeOH (5 mL). The reaction mixture was heated at reflux for 1.5 h, filtered (Celite) and 
the solvent was evaporated under reduced pressure. The residue was chromatographed on 
a silica gel column (Aldrich silica gel 60) using CH2Cl2/MeOH (95:5) as  eluent to give a 
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crude product (0.09 g, 81%) as a semisolid: 1H NMR (CDCl3) δ 2.58 (s, 6H, CH3), 2.93 
(t, 2H, CH2), 3.10 (t, 2H, CH2),  5.16 (s, 2H, CH2), 6.63 (d, 2H, ArH), 6.97 (d, 2H, ArH), 
6.97 (s, 1H, ArH), 7.13 (t, 1H, ArH), 7.20 (t, 1H, ArH), 7.33 (d, 1H, ArH), 7.62 (d, 1H, 
ArH). The product was converted to its hydrochloride salt in anhydrous Et2O by addition 
of HCl/Et2O. The orange precipitate was collected by filtration and recrystallized from 
MeOH/Et2O to give 33b (0.07 g,  61%) as a yellow powder: mp 157-159 °C; 1H NMR 
(DMSO-d6) δ 2.83 (s, 6H, CH3), 3.13 (t, 2H, CH2), 3.31 (t, 2H, CH2), 5.39 (s, 2H, CH2), 
7.05 (t, 1H, ArH), 7.13 (t, 1H, ArH), 7.20-7.27 (m, 4H, ArH), 7.38 (s, 1H, ArH), 7.44 (d, 
1H, ArH), 7.66 (d, 1H, ArH). Anal. calcd for C19H23N3 x 2HCl x 0.5 H2O : C, 60.81; H, 
6.98; N, 11.20 Found: C, 60.69; H, 6.76; N, 10.74. 
 
N,N-Dimethyl-2-[1-(4-methoxybenzyl)-1H-indol-3-yl]-1-aminoethane Oxalate (33c) 
 
A mixture of N,N-dimethyltryptamine (82) (0.50 g, 2.66 mmol) and 60% NaH (0.10 g, 
4.17 mmol) was heated at 100 °C under nitrogen until evolution of hydrogen gas ceased. 
The resultant product was dissolved in anhydrous DMF (5 mL), and 4-methoxybenzyl 
chloride (0.33 mL, 2.43 mmol) was added resulting in a solution at 0 °C. The reaction 
mixture was allowed to stir at room temperature for 3 h. Brine was added and the mixture 
was extracted with CH2Cl2 (2 x 50 mL). The organic portion was dried over MgSO4 and 
the solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel using CHCl3 and MeOH (12:1) as eluent to give 0.35 g of a 
brown yellow oil. The product was isolated as an oxalate salt to give 33c (0.25 g, 51%) as 
a white powder after recrystallization from anhydrous MeOH/Et2O: mp 172-173 °C; 1H 
NMR (DMSO-d6)  δ 2.79 (s, 6H, CH3), 3.08 (t, 2H, CH2), 3.25 (t, 2H, CH2), 3.68 (s, 3H, 
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CH3), 5.26 (s, 2H, CH2), 6.84 (d, 2H, ArH), 7.01-7.17 (m, 4H, ArH), 7.33 (s, 1H, ArH), 
7.45 (d, 1H, ArH), 7.60 (d, 1H, ArH). Anal. Calcd for C20H24N2O · C2H2O4 : C, 62.32; H, 
6.58; N, 7.03 Found: C, 62.23; H, 6.66; N, 7.07. 
 
N,N-Dimethyl-2-[1-(4-methylbenzyl)-1H-indol-3-yl]-1-aminoethane Oxalate (33d) 
 
N,N-Dimethyltryptamine (82) (0.32 g, 1.68 mmol) in dry THF (5 mL) was added in a 
dropwise manner to  a stirred mixture of potassium tert-butoxide (0.25 g, 2.18 mmol) and 
18-crown-6 (0.04 g, 1.68 mmol) in dry THF (10 mL). The reaction mixture was cooled at 
0 °C for 15 min, and then a solution of 4-methylbenzyl chloride (0.35 g, 2.52 mmol) in 
dry THF (5 mL) was added in a dropwise manner. The reaction mixture was allowed to 
stir at room temperature overnight, then concentrated and extracted with EtOAc (3 x 15 
mL). The combined organic portions were washed with brine (20 mL) and dried over 
Na2SO4. The solvent was evaporated under reduced pressure. The residue was 
chromatographed on a silica gel column using CH2Cl2/MeOH (9.5:0.5) as eluent to give 
0.13 g, of a brown yellow oil. The product was isolated as an oxalate salt to give 33d 
(0.13 g, 20%) as white powder after recrystallization from Me2CO: mp 179-182 °C; 1H 
NMR (DMSO-d6)  δ 2.23 (s, 3H, CH3), 2.82 (s, 6H, CH3), 3.07 (t, 2H, CH2), 3.28 (t, 2H, 
CH2), 5.30 (s, 2H, CH2), 7.00-7.15 (m, 6H, ArH), 7.34 (s, 1H, ArH), 7.42 (d, 1H, ArH), 
7.61 (d, 1H, ArH). Anal. Calcd for C20H24N2 · C2H2O4 : C, 69.09; H, 6.85; N, 7.32 
Found: C, 69.17; H, 6.98; N, 7.29. 
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N,N-Dimethyl-2-[1-(4-trifluorobenzyl)-1H-indol-3-yl]-1-aminoethane Oxalate (33e) 
 
N,N-Dimethyltryptamine (82) (0.32 g, 1.68 mmol) in dry THF (5 mL) was added in a 
dropwise manner to  a stirred mixture of potassium tert-butoxide (0.25 g, 2.18 mmol) and 
18-crown-6 (0.04 g, 1.68 mmol) in dry THF (10 mL). The reaction mixture was cooled at 
0 °C for 15 min, and then a solution of 4-(trifluoromethyl)benzyl chloride (0.49 g, 2.52 
mmol) in dry THF (5 mL) was added in a dropwise manner. The reaction mixture was 
allowed to stir at room temperature overnight, then concentrated and extracted with 
EtOAc (3 x 15 mL), washed with brine (20 mL) and dried over Na2SO4. The solvent was 
evaporated under reduced pressure. The residue was chromatographed on a silica gel 
column using CH2Cl2/MeOH (9.5:0.5) as eluent to give 0.25 g, of a brown yellow oil. 
The product was isolated as an oxalate salt to give 33e (0.18 g, 25%) as white powder 
after recrystallization from Me2CO: mp 162-163 °C; 1H NMR (DMSO-d6)  δ 2.82 (s, 6H, 
CH3), 3.07 (d, 2H, CH2), 3.27 (d, 2H, CH2), 5.48 (s, 2H, CH2), 7.04-7.13 (m, 2H, ArH), 
7.34-7.44 (m, 4H, ArH), 7.64-7.66 (m, 3H, ArH). Anal. Calcd for C20H21F3N2 · C2H2O4 : 
C, 60.54; H, 5.31; N, 6.41 Found: C, 60.60; H, 5.36; N, 6.43. 
 
N,N-Dimethyl-2-[1-(4-chlorobenzyl)-1H-indol-3-yl]-1-aminoethane Oxalate (33f) 
 
A mixture of N,N-dimethyltryptamine (82) (0.50 g, 2.66 mmol) and 60% NaH (0.10 g, 
4.17 mmol) was heated at 100 °C under nitrogen until evolution of hydrogen gas ceased. 
The resultant product was dissolved in anhydrous DMF (5 mL), and 4-chlorobenzyl 
chloride (0.54 g, 3.34 mmol) was added resulting in a solution at 0 °C. The reaction 
mixture was allowed to stir at room temperature for 3 h. Brine was added and the mixture 
was extracted with CH2Cl2 (2 x 50 mL). The organic portion was dried over MgSO4 and 
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the solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel using CH2Cl2 and MeOH (12:1) as eluent to give 0.40 g of 
a brown yellow oil. The product was isolated as an oxalate salt to give 33f (0.30 g, 61%) 
as a white powder after recrystallization from anhydrous MeOH/Et2O: mp 170-172 °C  ; 
1H NMR (DMSO-d6)  δ 2.80 (s, 6H, CH3), 3.09 (t, 2H, CH2), 3.27 (t, 2H, CH2), 5.36 (s, 
2H, CH2), 7.00-7.19 (m, 4H, ArH), 7.33-7.42 (m, 4H, ArH), 7.63 (d, 1H, ArH). Anal. 
Calcd for C19H21ClN2 · C2H2O4 : C, 62.60; H, 5.75; N, 6.95 Found: C, 62.35; H, 5.74; N, 
6.93. 
 
N,N-Dimethyl-2-[1-(3-chlorobenzyl)-1H-indol-3-yl]-1-aminoethane Oxalate (33g) 
 
N,N-Dimethyltryptamine (82) (0.32 g, 1.68 mmol) in dry THF (5 mL) was added in a 
dropwise manner to a stirred mixture of potassium tert-butoxide (0.25 g, 2.18 mmol) and 
18-crown-6 (0.04 g, 1.68 mmol) in dry THF (10 mL). The reaction mixture was cooled at 
0 °C for 15 min, and then a solution of 3-chlorobenzyl chloride (0.32 mL, 2.52 mmol) in 
dry THF (5 mL) was added in a dropwise manner. The reaction mixture was allowed to 
stir at room temperature overnight, then concentrated and extracted with EtOAc (3 x 15 
mL), washed with brine (20 mL) and dried (Na2SO4). The solvent was evaporated under 
reduced pressure. The residue was chromatographed on a silica gel column using 
CH2Cl2/MeOH (9.5:0.5) as eluent to give 0.24 g of a brown yellow oil. The product was 
isolated as an oxalate salt to give 33g (0.18 g, 27%) as white crystals after 
recrystallization from Me2CO: mp 140-141 °C; 1H NMR (DMSO-d6)  δ 2.51 (s, 6H, 
CH3), 3.10 (t, 2H, CH2), 3.27 (d, 2H, CH2), 5.40 (s, 2H, CH2), 7.06-7.14 (m, 3H, ArH), 
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7.25 (s, 1H, ArH), 7.32-7.47 (m, 4H, ArH), 7.64 (d, 1H, ArH). Anal. Calcd for 
C19H21ClN2 · C2H2O4 : C, 62.61; H, 5.75; N, 6.95 Found: C, 62.50; H, 5.69; N, 6.88. 
 
N,N-Dimethyl-2-[1-(3,4-dichlorobenzyl)-1H-indol-3-yl]-1-aminoethane Oxalate (33h) 
 
A mixture of N,N-dimethyltryptamine (82) (0.50 g, 2.66 mmol) and 60% NaH (0.10 g, 
4.17 mmol) was heated at 100 °C under nitrogen until evolution of hydrogen gas ceased. 
The resultant product was dissolved in anhydrous DMF (5 mL), and 3,4-dichlorobenzyl 
chloride (0.46 mL, 3.32 mmol) was added resulting in a solution at 0 °C. The reaction 
mixture was allowed to stir at room temperature for 3 h. Brine was added and the mixture 
was extracted with CH2Cl2 (2 x 50 mL). The organic portion was dried over MgSO4 and 
the solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel using CHCl3 and MeOH (12:1) as eluent to give 0.30 g of a 
brown yellow oil. The product was isolated as an oxalate salt to give 33h (0.11 g, 10%) 
as yellowish crystals after recrystallization from anhydrous MeOH/Et2O: mp 172-173 °C; 
1H NMR (DMSO-d6)  δ 2.79 (s, 6H, CH3), 3.09 (t, 2H, CH2), 3.27 (t, 2H, CH2),  5.38 (s, 
2H, CH2), 7.05 (t, 1H, ArH), 7.10-7.14 (m, 2H, ArH), 7.38-7.47 (m, 3H, ArH), 7.53-7.63 
(m, 2H, ArH). Anal. Calcd for C19H20Cl2N2 · C2H2O4 : C, 57.68; H, 5.07; N, 6.41 Found: 
C, 57.48; H, 5.12; N, 6.44. 
 
N,N-Dimethyl-2-[1-(Isopropylsulfonyl)-1H-indol-3-yl]-1-aminoethane Oxalate (78a) 
 
A mixture of N,N-dimethyltryptamine (82) (0.50 g, 2.66 mmol) and 60% NaH (0.10 g, 
2.52 mmol) was heated at 100 °C under nitrogen until evolution of hydrogen gas ceased. 
The resultant product was dissolved in anhydrous DMF (5 mL), and isopropylsulfonyl 
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chloride (0.32 mL, 2.87 mmol) was added resulting in a solution at 0 °C. The reaction 
mixture was allowed to stir at room temperature for 3 h. Brine was added and the mixture 
was extracted with CH2Cl2 (2 x 50 mL). The organic portion was dried over MgSO4 and 
the solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel using CH2Cl2 and MeOH (12:1) as eluent to give 0.39 g of 
a brown yellow oil. The product was isolated as an oxalate salt to give 78a (0.24 g, 24%) 
as white powder after recrystallization from anhydrous MeOH/Et2O: mp 175-178 °C; 1H 
NMR (DMSO-d6)  δ 1.19 (d, 6H, CH3), 2.82 (s, 6H, CH3), 3.16 (t, 2H, CH2), 3.37 (t, 2H, 
CH2), 3.72-3.79 (m, 1H, CH), 7.32-7.42 (m, 2H, ArH), 7.55 (s, 1H, ArH), 7.78-7.85 (m, 
2H, ArH). Anal. Calcd for (C15H22N2O2S)2 · C2H2O4 x 1.5 H2O : C, 54.44; H, 6.99; N, 
7.93 Found: C, 54.00; H, 7.08; N, 8.31. C, a difference of 0.44. 
 
N,N-Dimethyl-2-[1-(n-propylsulfonyl)-1H-indol-3-yl]-1-aminoethane Oxalate (78b) 
 
A mixture of N,N-dimethyltryptamine (82) (0.50 g, 2.66 mmol) and 60% NaH (0.10 g, 
2.52 mmol) was heated at 100 °C under nitrogen until evolution of hydrogen gas ceased. 
The resultant product was dissolved in anhydrous DMF (5 mL), and n-propylsulfonyl 
chloride (0.32 mL, 2.87 mmol) was added resulting in a solution at 0 °C. The reaction 
mixture was allowed to stir at room temperature for 3 h. Brine was added and the mixture 
was extracted with CH2Cl2 (2 x 50 mL). The organic portion was dried over MgSO4 and 
the solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel using CH2Cl2 and MeOH (12:1) as eluent to give 0.24 g of 
a brown yellow oil. The product was isolated as an oxalate salt to give 78b (0.13 g, 12%) 
as a white powder after recrystallization from anhydrous MeOH/Et2O: mp 144-145 °C; 
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1H NMR (DMSO-d6)  δ 0.86 (t, 6H, CH3), 1.51 (q, 4H, CH2), 2.82 (s, 12H, CH3), 3.15 (t, 
4H, CH2), 3.37 (t, 4H, CH2), 3.55 (t, 4H, CH2), 7.33-7.40 (m, 4H, ArH), 7.53 (s, 2H, 
ArH), 7.76-7.78 (m, 4H, ArH). Anal. Calcd for C30H44N4O4S2 · C2H2O4 : C, 54.44; H, 
6.99; N, 7.93 Found: C, 54.17; H, 6.99; N, 8.21. 
 
N,N-Dimethyl-2-[1-(n-butylsulfonyl)-1H-indol-3-yl]-1-aminoethane Oxalate (78c) 
 
A mixture of N,N-Dimethyltryptamine (82) (0.50 g, 2.66 mmol) and 60% NaH (0.10 g, 
2.52 mmol) was heated at 100 °C under nitrogen until evolution of hydrogen gas ceased. 
The resultant product was dissolved in anhydrous DMF (5 mL), and n-butylsulfonyl 
chloride (0.37 mL, 2.87 mmol) was added resulting in a solution at 0 °C. The reaction 
mixture was allowed to stir at room temperature for 3 h. Brine was added and the mixture 
was extracted with CH2Cl2 (2 x 50 mL). The organic portion was dried over MgSO4 and 
the solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel using CH2Cl2 and MeOH (12:1) as eluent to give 0.17 g of 
a brown yellow oil. The product was isolated as an oxalate salt to give 78c (0.03 g, 3%) 
as a white powder after recrystallization from anhydrous MeOH/Et2O: mp 162-163 °C; 
1H NMR (DMSO-d6)  δ 0.75 (s, 3H, CH3), 1.22-1.29 (m, 2H, CH2), 1.42-1.49 (m, 2H, 
CH2), 2.79 (s, 6H, CH3), 3.18 (d, 2H, CH2), 3.31 (d, 2H, CH2), 3.55 (t, 2H, CH2), 7.32-
7.43 (m, 2H, ArH), 7.53 (s, 1H, ArH), 7.75 (t, 1H, ArH), 7.83 (t, 1H, ArH). Anal. Calcd 
for C16H24N2O2S · C2H2O4 : C, 54.25; H, 6.57; N, 7.03 Found: C, 54.06; H, 6.64; N, 6.97. 
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N,N-Dimethyl-2-[1-(n-amylsulfonyl)-1H-indol-3-yl]-1-aminoethane Oxalate (78d) 
 
A mixture of N,N-dimethyltryptamine (82) (0.32 g, 1.68 mmol) in dry THF (5 mL) was 
added in a dropwise manner to  a stirred a mixture of potassium tert-butoxide (0.24 g, 
1.68 mmol) and 18-crown-6 (0.04 g, 1.68 mmol) in dry THF (10 mL). After cooling at 0 
°C for 15 min, a solution of n-amylsulfonyl chloride (90) (0.29 g, 1.68 mmol) in dry THF 
(5 mL) was added in a dropwise manner to the mixture of N,N-dimethyltryptamine, 
potassium tert-butoxide and 18-crown-6. The reaction mixture was allowed to stir at 
room temperature overnight, then concentrated and extracted with EtOAc (3 x 15 mL), 
washed with brine (20 mL) and dried with Na2SO4. The solvent was evaporated under 
reduced pressure. The residue was chromatographed on a silica gel column using 
CH2Cl2/MeOH (9.5:0.5) as eluent to give 0.12 g of a brown yellow oil. The product was 
isolated as an oxalate salt to give 78d (0.05 g, 7%) as a white powder after 
recrystallization from anhydrous MeOH/Et2O: mp 167-169 °C; 1H NMR (DMSO-d6)  δ 
0.75 (t, 3H, CH3), 1.14-1.20 (m, 4H, CH2), 1.48 (t, 2H, CH2), 2.80 (s, 6H, CH3), 3.10 (t, 
2H, CH2), 3.29 (t, 2H, CH2), 3.55 (t, 2H, CH2), 7.35-7.43 (m, 2H, ArH), 7.55 (s, 1H, 
ArH), 7.76 (d, 1H, ArH), 7.84 (d, 1H, ArH). Anal. Calcd for C17H26N2O2S · C2H2O4 : C, 
55.32; H, 6.84; N, 6.79 Found: C, 55.22; H, 6.93; N, 6.75. 
 
N,N-Dimethyl-2-[1-(n-octylsulfonyl)-1H-indol-3-yl]-1-aminoethane Oxalate (78e) 
 
A mixture of N,N-dimethyltryptamine (82) (0.50 g, 2.66 mmol) and 60% NaH (0.10 g, 
2.52 mmol) was heated at 100 °C under nitrogen until evolution of hydrogen gas ceased. 
The resultant product was dissolved in anhydrous DMF (5 mL), and n-octylsulfonyl 
chloride (0.56 mL, 2.87 mmol) was added resulting in a solution at 0 °C. The reaction 
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mixture was allowed to stir at room temperature for 3 h. Brine was added and the mixture 
was extracted with CH2Cl2 (2 x 50 mL). The organic portion was dried over MgSO4 and 
the solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel using CH2Cl2 and MeOH (12:1) as eluent to give 0.18 g of 
a brown yellow oil. The product was isolated as an oxalate salt to give 78e (0.06 g, 5%) 
as a white powder after recrystallization from anhydrous MeOH/Et2O: mp 138-139 °C; 
1H NMR (DMSO-d6)  δ 0.80 (t, 3H, CH3), 1.10-1.19 (m, 10H, CH2), 1.46 (t, 2H, CH2), 
2.78 (s, 6H, CH3), 3.09 (t, 2H, CH2), 3.30 (t, 2H, CH2), 3.53 (t, 2H, CH2), 7.33-7.41 (m, 
2H, ArH), 7.52 (s, 1H, ArH), 7.74 (d, 1H, ArH), 7.81 (d, 1H, ArH). Anal. Calcd for 
C20H32N2O2S · C2H2O4 : C, 58.12; H, 7.53; N, 6.16 Found: C, 57.67; H, 7.47; N, 6.14. C, 
a difference of 0.45. 
 
N,N-Dimethyl-2-[1-(cyclohexylsulfonyl)-1H-indol-3-yl]-1-aminoethane Oxalate (78f) 
 
A mixture of N,N-dimethyltryptamine (82) (0.32 g, 1.68 mmol) in dry THF (5 mL) was 
added in a dropwise manner to a stirred mixture of potassium tert-butoxide (0.25 g, 2.18 
mmol) and 18-crown-6 (0.04 g, 1.68 mmol) in dry THF (10 mL). The reaction mixture 
was cooled at 0 °C for 15 min, and then a solution of cyclohexylsulfonyl chloride (93) 
(0.46 g, 2.52 mmol) in dry THF (5 mL) was added in a dropwise manner. The reaction 
mixture was allowed to stir at room temperature overnight, then concentrated and 
extracted with EtOAc (3 x 15 mL). The combined organic portions were washed with 
brine (20 mL) and dried with Na2SO4. The solvent was evaporated under reduced 
pressure. The residue was chromatographed on a silica gel column using CH2Cl2/MeOH 
(9.5:0.5) as eluent to give 0.18 g of a brown yellow oil. The product was isolated as an 
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oxalate salt to give 78f (0.10 g, 14%) as a white powder after recrystallization from 
anhydrous MeOH/Et2O: mp 173-175 °C; 1H NMR (DMSO-d6)  δ 1.11 (m, 10H, CH2), 
2.75 (s, 6H, CH3), 3.04 (t, 2H, CH2), 3.29 (t, 2H, CH2), 3.54 (t, 1H, CH), 7.25-7.35 (m, 
2H, ArH), 7.45 (s, 1H, ArH), 7.69 (d, 1H, ArH), 7.78 (d, 1H, ArH). Anal. Calcd for 
C18H26N2O2S · C2H2O4 : C, 56.58; H, 6.64; N, 6.59 Found: C, 56.39; H, 6.77; N, 6.63. 
 
N,N-Dimethyltryptamine (82) 
 
Compound 82 was prepared following a literature113 procedure. Oxalyl chloride (2.97 
mL, 34.05 mmol) in N2-purged anhydrous Et2O (14 mL) was added dropwise to a 
solution of indole (4g, 34.04 mmol) in N2-purged mixture of anhydrous Et2O (27 mL), 
and THF (1.4 mL) at 0 ˚C under N2. The mixture was allowed to stir at 0 ˚C for 20 min 
and then at room temperature for 30 min. The bright yellow precipitate was collected by 
filtration and washed with anyhrous Et2O (40 mL) obtaining 3-indolylglyoxyl chloride 
(80) (6.73g). 
3-Indolylglyoxyl chloride (80) (6.73 g, 32.41 mmol) was added with rigorous stirring to 
30 mL of 40% dimethylamine in H2O. The mixture after sometime changed color from 
yellow to green. The mixture was allowed to stir overnight. The resulting solution was 
concentrated and the yellow precipitate was collected by filtration to give (4.69 g, 84 %) 
of a crude product (N,N-dimethyl-3-indolylglyoxylamide, 81); mp 152-155 ˚C (lit.129 mp 
159-160 ˚C). 
N,N-Dimethyl-3-indolylglyoxylamide (81) (5.69g, 26.32 mmol) as a solution in dry THF 
(32.8 mL) was added to a suspension of LiAlH4 in dry THF (100 mL) in a dropwise 
manner at 0 ˚C. The mixture was heated under reflux for 3 h. The mixture was cooled at 0 
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°C and the excess LiAlH4 was destroyed by addition of H2O (8.1 mL), NaOH (15%, 8.1 
mL) and H2O (24.3 mL) at 0 °C. The precipitate was removed by filtration and washed 
with 114 mL of hot THF. The filtrate was dried (MgSO4) and the solvent was evaporated 
under reduced pressure to give a crude product as an oil. Distillation at 180 °C (0.2 mbar) 
yielded 82 (3.16 g) (56%) as a colorless oil that solidified on standing; mp 49-50 ˚C 
(lit.113 mp 44-46 °C); 1H NMR (DMSO-d6)  δ 2.35 (s, 6H, CH3), 2.65 (t, 2H, CH2), 2.96 
(t, 2H, CH2), 7.01 (d, 1H, ArH), 7.14 (t, 1H, ArH), 7.19 (t, 1H, ArH), 7.34 (d, 1H, ArH), 
7.62 (d, 1H, ArH), 8.08 (s br, 1H, ArH).  
 
N1-(4-Nitrobenzyl)indole (83)116
 
Indoline-2-carboxylic acid (2.45 g, 15 mmol) was heated with 4-nitrobenzaldehyde (2.27 
g, 15 mmol) in MeCN (45 mL) overnight. The solvent was evaporated under reduced 
pressure, the residue was dissolved in H2O (50 mL) and extracted with EtOAc (3 x 35 
mL). The combined organic portions were dried (Na2SO4) and the solvent was 
evaporated under reduced pressure to give a dark, brown oil (4.05 g). Chromatography on 
a silica gel column (Aldrich silica gel 60) using CH2Cl2/hexane (1:1) as eluent  gave  
crude product (2.27 g, 60 %) as a yellow oil which solidified on standing: mp 94-97 °C; 
1H NMR (DMSO-d6) δ 5.54 (d, 1H, ArH), 7.03 (t, 1H, ArH), 7.10 (t, 1H, ArH), 7.36-7.42 
(m, 3H, ArH), 7.55 (d, 1H, ArH), 7.59 (d, 1H, ArH), 8.19 (d,2H, ArH). The title 
compound has been cited in the literature115 but was not characterized. 
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N1-(4-Aminobenzyl)indole (84) 
 
A solution of 83 (1.09 g, 4.3 mmol) and tin (II) chloride dihydrate (9.75 g, 43 mmol) in 
absolute EtOH (100 mL) was heated at reflux for 1 h. The reaction mixture was allowed 
to cool to room temperature and then a small amount of ice was added. The solution was 
made slightly basic (pH 8-9) by addition of a saturated solution of NaHCO3. Sodium 
chloride (ca. 4 g) was added to the solution and the mixture was extracted with EtOAc (2 
x  300 mL). The combined organic portions were thoroughly washed with brine and dried 
(Na2SO4). The solvent was evaporated under reduced pressure to give a product as a 
yellow oil (0.81 g, 84%). The product was used in the next step without further 
purification. 
 
N1-[4-(Dibenzylamino)benzyl]indole (85) 
 
Benzyl bromide (2.14 mL, 18 mmol) was added in a dropwise manner over 30 min to a 
well-stirred suspension of 84 (0.80 g, 3.6 mmol) in CH2Cl2 (10 mL) and triethylamine 
(1.52 mL, 10.8 mmol); this was allowed to stir for an additional 2 h. The solution was 
concentrated and the residue was chromatographed on a silica gel column (Aldrich silica 
gel 60) using hexane/CH2Cl2 (7:3) as eluent to give a crude product (1.31 g, 90 %) as a 
yellow oil. The product was used in the next step without further characterization. 
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(N1-[4-Dibenzylaminobenzyl]-3-[carboxaldehyde]) indole (86) 
 
Phosphorus oxotrichloride (0.32 mL, 3.55 mmol) was added via a syringe to ice-cooled 
dry DMF (10 mL). The solution protected from moisture with a drying tube, was allowed 
to stir at room temperature for 15 min and then cooled to 0 ˚C. A solution of 85 (1.31 g, 
3.25 mmol) in dry DMF (5 mL) was added over 5 min, and the solution was allowed to 
stir at room temperature for 2 h, poured into a mixture of ice and aqueous NaOH (1 N) 
and extracted with CH2Cl2 (3 x 30 mL). The combined organic portions were washed 
with H2O (50 mL) and brine (50 mL), and dried (Na2SO4). The solvent was evaporated 
under reduced pressure to give the crude product (1.18 g, 84%) as a yellow solid: mp 
137-138 °C. The homogenous product was used in the following reaction step without 
further purification. This compound has not been cited in the literature. 
 
(N1-[4-Dibenzylaminobenzyl]-3-[2-nitrovinyl])indole (87) 
 
A mixture of 86 (0.99 g, 2.3 mmol), ammonium acetate (0.09 g, 015 mmol) and MeNO2 
(8 mL) was heated at reflux for 3 h, then the solvent was evaporated under reduced 
pressure. The residue was dissolved in CH2Cl2, washed with H2O (30 mL) and the 
solution dried (Na2SO4). The solvent was removed under reduced pressure to give the 
crude product (1.05 g, 96%) as a yellow oil: 1H NMR (CDCl3) δ 4.68 (s, 4H, CH2), 5.21 
(s, 2H, CH2), 6.77 (d, 2H, ArH), 7.04 (d, 2H, CH2), 7.26-7.37 (m, 14H, ArH), 7.50 (s, 1H, 
ArH), 7.77 (d, 1H, ArH), 7.25 (d, 1H, ArH). 
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Amylsulfonyl chloride (90) 
 
Cyanuric chloride (0.922 g, 5 mmol) (89) was added to a mixture of sodium n-
amylsulfonate (88) (0.871g, 5 mmol) and 0.25 mmol of 18-crown-6 ether in 10 mL of 
Me2CO and the mixture was heated under reflux for 20 h under anhydrous conditions. 
After cooling the reaction mixture to room temperature the solution was filtered (celite 
pad). The solvent was removed under reduced pressure and the crude product was 
purified by Kugelrohr distillation yielding n-amylsulfonyl chloride (90) (0.51, 56%); 1H 
NMR (DMSO-d6) δ 0.97 (t, 3H, CH3), 1.41-1.45 (m, 4H, CH2), 2.05 (t, 2H, CH2), 3.67 (t, 
2H, CH2). This compound was used in the next step without further characterization. 
 
Cyclohexylsulfonyl chloride (93) 
 
Chlorine was bubbled through a solution of cyclohexylthiol (10.0 g) in 48 mL of acetic 
acid and 4.5 mL of water, maintained at 10-15 °C, until the yellow color persisted. 
Nitrogen was then bubbled through the resulting mixture to remove excess chlorine. The 
resulting mixture was poured into ice and then extracted with CH2Cl2 (3 x 30 mL). The 
combined CH2Cl2 extract was washed with H2O (10 mL), 5% NaOH (10 mL), again with 
H2O (10 mL), and then dried (Na2SO4). The solvent was removed under reduced pressure 
followed by Kugelrohr distillation of the residue to yield 3.1 g (23%) of 
cyclohexylsulfonyl chloride (93) as a yellowish liquid; 1H NMR (DMSO-d6) δ 1.33-1.39 
(m, 3H, CH2), 1.74-1.75 (m, 3H, CH2), 1.98-2.17 (m, 2H, CH2), 2.41-2.44 (m, 2H, CH2), 
3.46-3.55 (m, 1H, CH). The bp of this compound was not determined. 
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B. Binding Assay 
The h5-HT6 radioligand binding assay was performed as previously described.71 In brief, 
h5-HT6 cDNA was transiently expressed in HEK-293 cells using Fugene6 according to 
the manufacturer’s recommendations; 24 h after transfection the medium was replaced, 
and 24 h later, medium containing dialyzed serum (to remove 5-HT) was added. At 72 h 
after transfection, cells were harvested by scraping and centrifugation. Cells were then 
washed by centrifugation and resuspention in phosphate-buffered saline (pH = 7.40; 
PBS) and frozen as tight pellets at -80 °C until use. Binding assays were performed at 
room temperature for 90 min in binding buffer (50 mM Tris-Cl, 10 mM MgCl2, 0.1 mM 
EDTA, pH = 7.40) with [3H]LSD (1 nM final concentration) using 10 µM clozapine for 
non specific binding. Concetrations of unlabeled test agent were used for Ki 
determinations with Ki values calculated using the program GraphPad Prism (V4.0). 
Specific binding represented 80-90% of total binding. Ki values are the result of triplicate 
determinations. 
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